

October 2011 Volume 66 Supplement 2

Thorax

AN INTERNATIONAL JOURNAL OF RESPIRATORY MEDICINE

**Guidelines for the management of
community acquired pneumonia in
children: update 2011**

**British Thoracic Society
Community Acquired Pneumonia in
Children Guideline Group**

thorax.bmj.com



BMJ Journals

**Michael Harris, Julia Clark, Nicky Coote, Penny Fletcher,
Anthony Harnden, Michael McKean,
Anne Thomson**

**Community Acquired Pneumonia in Children Guideline Group
On behalf of the British Thoracic Society
Standards of Care Committee**





Journal of the British Thoracic Society

Impact Factor: 6.53

Editors

A Bush (UK)
I Pavord (UK)

Deputy Editors

P Cullinan (UK)
C Lloyd (UK)

Associate Editors

R Beasley (New Zealand)	A Jones (UK)
J Brown (UK)	E Lim (UK)
JC Celedón (USA)	N Maskell (UK)
A Custovic (UK)	JL Pepin (France)
A Fisher (UK)	T Sethi (UK)
P Gibson (Australia)	M Steiner (UK)
J Grigg (UK)	D Thickett (UK)
D Halpin (UK)	H Zar (South Africa)

Statistical Editors

J Gibson (UK)

Statistical Advisor

T McKeever (UK)

Lung Alert Editor

J Quint (UK)

President, British Thoracic Society

E Neville

Editorial Office

BMJ Publishing Group Ltd, BMA House,
Tavistock Square, London WC1H 9JR, UK

T: +44 (0)20 7383 6373

F: +44 (0)20 7383 6668

E: thorax@bmjgroup.com

ISSN: 0040-6376 (print)

ISSN: 1468-3296 (online)

Disclaimer: *Thorax* is owned and published by the British Thoracic Society and BMJ Publishing Group Ltd, a wholly owned subsidiary of the British Medical Association. The owners grant editorial freedom to the Editor of *Thorax*.

Thorax follows guidelines on editorial independence produced by the World Association of Medical Editors and the code on good publication practice of the Committee on Publication Ethics.

Thorax is intended for medical professionals and is provided without warranty, express or implied. Statements in the Journal are the responsibility of their authors and advertisers and not authors' institutions, the BMJ Publishing Group Ltd, the British Thoracic Society or the BMA unless otherwise specified or determined by law. Acceptance of advertising does not imply endorsement.

To the fullest extent permitted by law, the BMJ Publishing Group Ltd shall not be liable for any loss, injury or damage resulting from the use of *Thorax* or any information in it whether based on contract, tort or otherwise. Readers are advised to verify any information they choose to rely on.

Copyright: © 2011 BMJ Publishing Group Ltd and the British Thoracic Society. All rights reserved; no part of this publication may be reproduced, stored in a retrieval system or transmitted in any form or by any means, electronic, mechanical, photocopying, recording or otherwise without the prior permission of *Thorax*.

Thorax is published by BMJ Publishing Group Ltd, typeset by TNQ Books & Journals, Chennai, India and printed in the UK on acid-free paper by Buxton Press, Buxton, UK.

Thorax (ISSN No: 0040-6376) is published monthly by BMJ Publishing Group and distributed in the USA by Mercury International Ltd. Periodicals postage paid at Rahway, NJ. POSTMASTER: send address changes to *Thorax*, Mercury International Ltd, 365 Blair Road, Avenel, NJ, 07001, USA.

Contents

Volume 66 Supplement 2 | **THORAX** October 2011

BTS guidelines

- ii1 Abstract
 - ii1 Synopsis of recommendations
 - ii2 1. Introduction and methods
 - ii3 2. Incidence and economic consequences
 - ii5 3. Aetiology
 - ii8 4. Clinical features
 - ii9 5. Radiological, general and microbiological investigations
 - ii13 6. Severity assessment
 - ii14 7. General management in the community and in hospital
 - ii15 8. Antibiotic management
 - ii18 9. Complications and failure to improve
 - ii19 10. Prevention and vaccination
 - ii20 11. Audit criteria
 - ii20 References
- Online Appendix 1** Search strategy
- Online Appendix 2** Template data collection form



EDITOR'S CHOICE

This article has been chosen by the Editor to be of special interest or importance and is freely available online.



Articles carrying the Unlocked Logo are freely available online under the BMJ Journals unlocked scheme. See <http://thorax.bmj.com/info/unlocked.dtl>

C

O

P

E

COMMITTEE ON PUBLICATION ETHICS

This journal is a member of and subscribes to the principles of the Committee on Publication Ethics

www.publicationethics.org.uk

equator
network

recycle

When you have finished with this magazine please recycle it.

British Thoracic Society guidelines for the management of community acquired pneumonia in children: update 2011

Michael Harris,¹ Julia Clark,² Nicky Coote,³ Penny Fletcher,⁴ Anthony Harnden,⁵ Michael McKean,⁶ Anne Thomson,¹ On behalf of the British Thoracic Society Standards of Care Committee

► Additional appendices are published online only. To view these files please visit the journal online (<http://thorax.bmj.com>).

¹Oxford Children's Hospital, The John Radcliffe, Headington, Oxford, UK

²Department of Paediatric Immunology and Infectious Diseases, Old COPD, Great North Children's Hospital, Royal Victoria Infirmary, Newcastle upon Tyne, UK

³Children's Ambulatory Unit, Hammersmith Hospital, Imperial College Healthcare NHS Trust, London, UK

⁴Pharmacy Department, Imperial College Healthcare NHS Trust, St Mary's Hospital, London, UK

⁵Department of Primary Health Care, University of Oxford, Headington, Oxford, UK

⁶Department of Paediatric Respiratory Medicine, Royal Victoria Infirmary, Newcastle upon Tyne, UK

Correspondence to

Anne Thomson, Oxford Children's Hospital, The John Radcliffe, Headley Way, Headington, Oxford OX3 9DU, UK; anne.thomson@orh.nhs.uk

Received 10 June 2011

Accepted 16 June 2011

ABSTRACT

The British Thoracic Society first published management guidelines for community acquired pneumonia in children in 2002 and covered available evidence to early 2000. These updated guidelines represent a review of new evidence since then and consensus clinical opinion where evidence was not found. This document incorporates material from the 2002 guidelines and supersedes the previous guideline document.

SYNOPSIS OF RECOMMENDATIONS

Clinical features

- Bacterial pneumonia should be considered in children when there is persistent or repetitive fever $>38.5^{\circ}\text{C}$ together with chest recession and a raised respiratory rate. [D]

Investigations

- Chest radiography should not be considered a routine investigation in children thought to have community acquired pneumonia (CAP). [A-]
- Children with signs and symptoms of pneumonia who are not admitted to hospital should not have a chest x-ray. [A-]
- A lateral x-ray should not be performed routinely. [B-]
- Acute phase reactants are not of clinical utility in distinguishing viral from bacterial infections and should not be tested routinely. [A-]
- C reactive protein is not useful in the management of uncomplicated pneumonia and should not be measured routinely. [A+]
- Microbiological diagnosis should be attempted in children with severe pneumonia sufficient to require paediatric intensive care admission, or those with complications of CAP. [C]
- Microbiological investigations should not be considered routinely in those with milder disease or those treated in the community. [C]
- Microbiological methods used should include:
 - Blood culture. [C]
 - Nasopharyngeal secretions and/or nasal swabs for viral detection by PCR and/or immunofluorescence. [C]
 - Acute and convalescent serology for respiratory viruses, *Mycoplasma* and *Chlamydia*. [B+]
 - If present, pleural fluid should be sent for microscopy, culture, pneumococcal antigen detection and/or PCR. [C]

- Urinary pneumococcal antigen detection should not be done in young children. [C]

Severity assessment

- For a child in the community, re-consultation to the general practitioner with persistent fever or parental concern about persistent fever should prompt consideration of CAP. [D]
- Children with CAP in the community or in hospital should be reassessed if symptoms persist and/or they are not responding to treatment. [D]
- Children who have oxygen saturations $<92\%$ should be referred to hospital for assessment and management. [B+]
- Auscultation revealing absent breath sounds with a dull percussion note should raise the possibility of a pneumonia complicated by effusion and should trigger a referral to hospital. [B-]
- A child in hospital should be reassessed medically if there is persistence of fever 48 h after initiation of treatment, increased work of breathing or if the child is becoming distressed or agitated. [D]

General management

- Families of children who are well enough to be cared for at home should be given information on managing fever, preventing dehydration and identifying any deterioration. [D]
- Patients whose oxygen saturation is $\leq 92\%$ while breathing air should be treated with oxygen given by nasal cannulae, high flow delivery device, head box or face mask to maintain oxygen saturation $>92\%$. [B]
- Nasogastric tubes may compromise breathing and should therefore be avoided in severely ill children and especially in infants with small nasal passages. If use cannot be avoided, the smallest tube should be passed down the smallest nostril. [D]
- Plasma sodium, potassium, urea and/or creatinine should be measured at baseline and at least daily when on intravenous fluids. [C]
- Chest physiotherapy is not beneficial and should not be performed in children with pneumonia. [A-]

Antibiotic management

- All children with a clear clinical diagnosis of pneumonia should receive antibiotics as bacterial

and viral pneumonia cannot reliably be distinguished from each other. [C]

- ▶ Children aged <2 years presenting with mild symptoms of lower respiratory tract infection do not usually have pneumonia and need not be treated with antibiotics but should be reviewed if symptoms persist. A history of conjugate pneumococcal vaccination gives greater confidence to this decision. [C]
- ▶ Amoxicillin is recommended as first choice for oral antibiotic therapy in all children because it is effective against the majority of pathogens which cause CAP in this group, is well tolerated and cheap. Alternatives are co-amoxiclav, cefaclor, erythromycin, azithromycin and clarithromycin. [B]
- ▶ Macrolide antibiotics may be added at any age if there is no response to first-line empirical therapy. [D]
- ▶ Macrolide antibiotics should be used if either mycoplasma or chlamydia pneumonia is suspected or in very severe disease. [D]
- ▶ In pneumonia associated with influenza, co-amoxiclav is recommended. [D]
- ▶ Antibiotics administered orally are safe and effective for children presenting with even severe CAP and are recommended. [A+]
- ▶ Intravenous antibiotics should be used in the treatment of pneumonia in children when the child is unable to tolerate oral fluids or absorb oral antibiotics (eg, because of vomiting) or presents with signs of septicaemia or complicated pneumonia. [D]
- ▶ Recommended intravenous antibiotics for severe pneumonia include amoxicillin, co-amoxiclav, cefuroxime and cefotaxime or ceftriaxone. These can be rationalised if a microbiological diagnosis is made. [D]
- ▶ In a patient who is receiving intravenous antibiotic therapy for the treatment of CAP, oral treatment should be considered if there is clear evidence of improvement. [D]

Complications

- ▶ If a child remains feverish or unwell 48 h after treatment has commenced, re-evaluation should be performed with consideration given to possible complications. [D]
- ▶ Children with severe pneumonia, empyema and lung abscesses should be followed up after discharge until they have recovered completely and their chest x-ray has returned to near normal. [D]

Follow-up

- ▶ Follow-up radiography is not required in those who were previously healthy and who are recovering well, but should be considered in those with a round pneumonia, collapse or persisting symptoms. [B+]

1. INTRODUCTION AND METHODS

The British Thoracic Society (BTS) first published management guidelines for community acquired pneumonia (CAP) in children in 2002 and covered available evidence to early 2000. These updated guidelines represent a review of new evidence since then and consensus clinical opinion where evidence was not found. As before, these guidelines have been produced in parallel with those produced for adults, which have also been updated. This document incorporates material from the 2002 guidelines and supersedes the previous guideline document.

CAP can be defined clinically as the presence of signs and symptoms of pneumonia in a previously healthy child due to an

infection which has been acquired outside hospital. In developed countries this can be verified by the radiological finding of consolidation. In the developing world a more practical term—acute lower respiratory tract infection—is preferred, reflecting the difficulties in obtaining an x-ray.

Ideally, the definition would include the isolation of a responsible organism. However, it is apparent from many studies that a pathogen is not identified in a significant proportion of cases that otherwise meet the clinical definition (see Section 3). As it is assumed that CAP is caused by infection, the presumption is that current techniques have insufficient sensitivity to detect all relevant pathogens. Treatment guidelines therefore have to assume that, where pathogens are isolated, they represent all likely pathogens. There is a clear need for better diagnostic methods.

In creating guidelines it is necessary to assess all available evidence with consideration of the quality of that evidence. This we have endeavoured to do. We have then produced a combination of evidence statements and recommendations about management based on the available evidence, supplemented by consensus clinical opinion where no relevant evidence was found.

The guideline is framed in each chapter as a list of key questions that are then explored and discussed. These questions were set based upon previous guidelines and those raised in the adult CAP guideline.

Methods of guideline development

Scope of guidelines

These guidelines address the management of CAP in infants and children in the UK. They do not include neonates, infants with respiratory syncytial virus bronchiolitis or children with upper respiratory tract infection, mild fever and wheeze. The specific management of children with pre-existing respiratory disease or that of opportunistic pneumonias in immunosuppressed children is not addressed.

Guideline development group

The guideline development group was set up by the BTS Standards of Care Committee and comprised two paediatricians with a special interest in respiratory disease, a paediatrician with a special interest in paediatric infectious diseases, a general paediatrician with a special interest in ambulatory paediatrics, a specialist trainee in paediatrics, a general practitioner with an interest in childhood infection and a paediatric pharmacist. An information specialist developed the search strategy and ran the searches. No external funding was obtained to support the development of the guidelines.

Identification of evidence

A search strategy was developed by an information specialist from the Centre for Reviews and Dissemination in York (part of the National Institute for Health Research). The Search strategy and the results are shown in appendix 1 in the online supplement.

The Cochrane Library (DARE and Cochrane Database of Systematic Reviews), MEDLINE and EMBASE were searched from 2000 onwards. There were some technical changes made to the original search strategies to reduce the chances of missing studies: a single search strategy was used rather than separate strategies for each subject. Studies were limited to English language in view of the limitations on time and resources.

Two thousand and seventy-six studies were identified by the searches, which were rerun in July 2010. The updated search identified a further 511 titles.

Assessing the literature

Initial review of the 2076 titles and abstracts was undertaken by one reviewer, screening for relevance. This was repeated after the second search by another reviewer. The relevant titles and abstracts were grouped by subject matter with many papers being relevant for more than one subject area.

Two reviewers then assessed the studies for inclusion. Studies from countries where the populations or clinical practices were very different from the UK were excluded unless they addressed questions that could be generalised to the UK (such as clinical assessment). Any differences of opinion were settled by a third party. The studies were appraised using the Cochrane data extraction template (see appendix 2 in online supplement).

Any guideline statements made were graded using the same table as that used by the group developing the adult guidelines (table 1).¹ First, each paper was given an evidence level (Ia to IVb) by the authors of each chapter. Then, at the end of each chapter when evidence statements were collated, a summative evidence level was attached to each statement depending on the level of evidence underpinning that statement. Finally, each recommendation was graded (A to D) based upon a considered judgement of the body of evidence.

Review of the guideline

The guideline is due for review in 3 years from the date of publication.

Provenance and peer review

The draft guideline was made available online for public consultation (January/February 2011). The draft guideline was reviewed by the BTS Standards of Care Committee (July 2010/ March 2011).

2. INCIDENCE AND ECONOMIC CONSEQUENCES

2.1 How common is CAP in children in the community and in hospital?

Two recent European papers give incidence rates for CAP in children seen in hospital (table 2) which are lower than those reported previously from the 1980s in Finland.^{2[1b]}

A prospective population-based study of 278 Norwegian children aged <16 years seen in hospital with pneumonia

(temperature, clinical signs and chest x-ray infiltrate in previously well child) from 2003 to 2005 in Oslo gave population incidence rates per 10 000 of 14.7 in children aged 0–16 years, 32.8 in those aged 0–5 years and 42.1 in those aged 0–2 years.^{3[III]}

UK data for children seen at hospital with pneumonia (clinical findings and chest x-ray) in 2001–2 (n=750) from a prospective population-based study in 13 hospitals in the north of England are remarkably similar with overall incidence rates of 14.4 per 10 000 in children aged 0–16 years per annum and 33.8 for those aged <5 years. Rates of those admitted to hospital were less at 12.2 (11.3–13.2) in children aged 0–16 years and 28.7 (26.2–31.4) in those aged 0–5 years.^{4[III]}

A population-based study performed in Kiel, Germany from 1996 to 2000 of children (n=514) with severe (ie, hospitalised) pneumonia (clinical assessment plus chest x-ray in 96.1%) included children with comorbidities (22.8%) and almost certainly what in the UK would be called bronchiolitis.^{5[III]} The overall incidence per 10 000 was 30 in children aged 0–16 years, 65.8 in those aged 0–5 years and 111.3 in those aged 0–1 year. A series of retrospective population-based cohort studies from the same Schleswig-Holstein area of Germany conducted in 1999–2001 from parental interviews at school entry permitted the calculation of population-based incidence of all CAP diagnosed by physician as 181.1/10 000 in children aged 0–1 year and 150.5/10 000 in those aged 0–5 years.^{6[III]}

Further estimates of pneumonia incidence can be obtained from the PRI.DE (Paediatric Respiratory Infection in Germany) study.^{7[III]} This prospective cohort study was designed to represent the German population of children aged <3 years and included children with lower respiratory tract infection (including pneumonia, wheeze, bronchitis, bronchiolitis and croup) presenting to primary or secondary care from 1999 to 2001. A total of 2386 children were seen as outpatients (2870/10 000 population, 95% CI 2770 to 2970) and 114 were given a clinical diagnosis of pneumonia (137/10 000). In addition, 2924 inpatients (294/10 000 population, 95% CI 284 to 304) were included in the study with 1004 given a clinical diagnosis of pneumonia (101/10 000).

The incidence of all-cause and pneumococcal pneumonia in children aged <2 years and pneumococcal pneumonia in children aged 2–4 years decreased in the USA after pneumococcal vaccination (PCV) became universal.^{8[III]} In the UK, admission rates for childhood pneumonia decreased by 19% between 2006 and 2008 to 10.79/10 000 following the introduction of conjugate pneumococcal vaccine (PCV7) to the national childhood immunisation programme.^{9[III]}

2.2 Are there pathogen-specific incidence rates?

As discussed in Section 3, determining the aetiology of pneumonia is critically dependent on the thoroughness of the search and the methods used. Recently there have been attempts to estimate the contribution of pneumococcal disease. Data from an enhanced surveillance system for laboratory-confirmed invasive pneumococcal disease (IPD) in England and Wales from 1996 to 2000, together with hospital episode statistics for codes related to pneumonia or pneumococcal disease and data from weekly Royal College of General Practitioner returns, were examined.^{7[III]} Age-specific incidence rates per 100 000 population were calculated for non-meningitis confirmed IPD and ranged from 59.7 in infants aged <1 month to 0.8 in children aged 10–14 years (table 3). These rates are lower than the pre-conjugate vaccine data on hospital admissions coded for pneumonia with pneumococcal disease from the USA.^{9[III]}

Table 1 Brief description of the generic levels of evidence and guideline statement grades used

Evidence level	Definition	Guideline statement grade
Ia	A good recent systematic review of studies designed to answer the question of interest	A+
Ib	One or more rigorous studies designed to answer the question, but not formally combined	A–
II	One or more prospective clinical studies which illuminate, but do not rigorously answer, the question	B+
III	One or more retrospective clinical studies which illuminate, but do not rigorously answer, the question	B–
IVa	Formal combination of expert views	C
IVb	Other information	D

Table 2 Incidence per 10 000 population

Country	Disease	Definition of pneumonia	Age 0–1 year (95% CI)	Age 0–2 years (95% CI)	Age 0–3 years (95% CI)	Age 0–5 years (95% CI)	Age 0–16 years (95% CI)
Whole population data							
Norway	Pneumonia	Signs and CXR		42.1 (32 to 52.3)		32.8 (26.8 to 38.8)	14.7 (12.2 to 17.1)
UK	Pneumonia	Signs and CXR				33.8 (31.1 to 36.7)	14.4 (13.4 to 15.4)
Germany (PRI.DE)	Pneumonia	Clinical including comorbidity			137		
Germany (Schleswig-Holstein)	Pneumonia	Clinical by parental interview	181.1			150.1	
Admitted to hospital							
UK	Pneumonia	Signs and CXR				28.7 (26.2 to 31.4)	12.2 (11.3 to 13.2)
Germany (Kiel)	Pneumonia and bronchiolitis	Signs and CXR including comorbidity	111.3			65.8	30
Germany (PRI.DE)	Pneumonia	Clinical including comorbidity			107		
USA	All-cause pneumonia	Coding including comorbidity		129.6			

CXR, chest x-ray.

2.3 Are there any known risk factors?

In the UK study,^{4[III]} boys had higher incidence rates at all ages. Severe disease as assessed by the BTS management guidelines published in 2002 was significantly more likely in children aged <5 years (19.4 (95% CI 17.4 to 21.7)/10 000 per year; OR 1.5, 95% CI 1.07 to 2.11) and in those born at 24–28 weeks gestation compared with those born at >37 weeks (OR 4.02, 95% CI 1.16 to 13.85).

When based on the pattern of changes on the chest x-ray (defined as patchy, lobar or perihilar), patchy pneumonic changes were more common in those aged <5 years (18.7/10 000) than lobar (5.6/10 000) and perihilar changes (7.2/10 000) while, in those aged 5–15 years, the rates of patchy, lobar and perihilar changes were 2.7/10 000, 0.9/10 000 and 0.5/10 000, respectively. Overall, lobar pneumonia accounted for only 17.6% of all cases.

The use of gastric acid inhibitors is associated with an increased risk of pneumonia in adults. A single study has suggested this may also be true in children.^{10[III]}

2.3.1 What is the effect of seasonality?

A marked seasonal pattern with winter preponderance was seen for laboratory-reported IPD and hospital admissions due to confirmed pneumococcal infection. December and January showed a peak 3–5 times higher than August.^{11[III]} Senstad *et al* also reported a low incidence of hospital CAP in summer and a peak in January.^{3[III]} There is marked seasonal variation in viral infections such as respiratory syncytial virus (RSV), influenza and parainfluenza 1+2.^{11[III]12[III]13[III]} Parainfluenza 3, however, is found throughout the year.^{7[II]}

Table 3 Incidence rate per 100 000 population

Age group	Pneumococcal sepsis and pneumonia (UK)	CI	Pneumococcal pneumonia (USA)
>1 month	59.7	50.8 to 64.8	
1–11 months	23.4	21.7 to 25.2	
0–2 years			26.2
1–4 years	9.9	9.4 to 10.4	
2–4 years			27.2
5–9 years	1.8	1.6 to 2	
5–17 years			3.5
10–14 years	0.8	0.7 to 1	

Mycoplasma infection occurs in clusters but has no clear seasonality.

2.4 What are the economic consequences of CAP in children?

A number of recent studies have examined the economic costs of CAP. An Italian study of 99 children hospitalised with pneumonia in 1999^{12[III]} calculated the costs of hospital management. The mean cost per patient was €1435 (£1289), increasing to €2553 (£2294) in those treated solely with intravenous antibiotics. The costs were reduced to €1218 (£1094) in those switched to the oral route after 24–48 h and to €1066 (£958) in those treated exclusively with oral antibiotics.

In the PRI.DE study of infants and children up to 36 months of age with lower respiratory tract infection, economic resource data were collected.^{13[III]} A total of 1329 cases in primary care and 2039 hospitalised cases were analysed. For those classified as pneumonia, direct medical costs were €85 (£76) per office-based case and €2306 (£2072) per hospitalised case. Parental costs amounted to a further €53 (£47) per office-based case and €118 (£106) per hospitalised case. In an Israeli study, further information on indirect family costs for a child with CAP—such as days of work missed, travel costs to primary/secondary care—amounted to 976 Israeli shekels (£161) for hospitalised patients, 747 (£123) for those seen at emergency facilities and 448 (£73) for those seen in primary care.^{14[III]}

Resource use data were routinely collected in the North of England CAP study 2001–2 (J Clark, personal communication, 2009^[IVb]). This included preadmission GP visits, antibiotics prescribed in the community and in hospital, and number of days of hospital care including any intensive care. Standard NHS list cost data were applied and inflated to 2005/6 levels. The average cost per admitted patient (n=636) was £2857. The mean cost for severe pneumonia was £3513 (mean hospital stay 5.5 days), falling to £2325 in moderate (hospital stay 4.7 days) and £909 in mild cases (hospital stay 1.7 days). Hospitalisation (non-intensive care) costs accounted for 70% of the total with a further 25% accounted for by intensive care stays. Cost analysis has also been performed on the PIVOT trial, a randomised controlled equivalence trial that demonstrated therapeutic equivalence for oral amoxicillin and intravenous benzyl penicillin in children admitted to hospital.^{15[III]} The average costs to the health service were lower at £1410 for intravenous treatment and £937 for oral treatment, demonstrating cost savings of £473–518 per child when oral amoxicillin was used.

Overall, therefore, the potential annual direct medical costs of children aged 0–16 years admitted to hospital in the UK with pneumonia are £12–18 000/10 000 per annum. According to the Office for National Statistics (2007) the UK population aged 0–16 years is 11.509 million. Therefore, £13–20 million per annum is spent on children with CAP admitted to hospital. In addition, there are direct costs to families and indirect costs to the economy from parental time off work.

Evidence statements

- ▶ The European incidence of CAP, defined as fever, clinical signs and chest radiograph infiltrate in a previously well child is approximately 33/10 000 in those aged 0–5 years and 14.5/10 000 in those aged 0–16 years. [Ib]
- ▶ Boys have a higher incidence at all ages. Children <5 years of age and those born between 24 and 28 weeks gestation have a higher incidence of severe disease. [III]

3. AETIOLOGY

Studies of the aetiology of CAP are complicated by the low yield of blood cultures,^{16[II]17[Ib]18[II]19[II]20[II]} the difficulty in obtaining adequate sputum specimens and the reluctance to perform lung aspiration and bronchoalveolar lavage in children.

Other factors which also limit the ability to extrapolate the results of published studies to other populations include the season of the year in which the study was done; the age of those studied; the setting; whether or not the children were admitted to hospital and the local criteria for admission, as well as whether or not the study period coincides with an epidemic of a certain pathogen. It is now further complicated by the increasing numbers of studies using specific serological or PCR techniques that include relatively small sample sizes. However, over the last 10 years PCR techniques have developed considerably and have been applied to viral detection on nasopharyngeal aspirates or secretions, thus increasing respiratory viral identification, and also to blood, increasing pneumococcal detection.^{21[II]22[Ib]}

3.1 What are the causes of CAP?

Studies of specific pathogens in developed countries are summarised in table 4. All of these are prospective studies in which the pneumonia was community acquired and where the case definition includes clinical findings compatible with pneumonia together with radiological changes. All constitute levels of evidence of Ib or II (indicated). In the columns the percentage indicates the percentage of all CAP cases in which that organism was detected. Where both viral and bacterial isolates were detected, it was classified as mixed and indicated in a separate column. In some studies it was not possible to determine whether infections were single or mixed (as indicated). Bacterial isolates are not included if isolated from a sputum or upper respiratory tract specimen in the absence of other evidence of significance—for example, a rise in antibody concentrations.

The studies are updated from the previous guidelines and cover years 2000–10. Only two come from a UK population although several are from Europe. Most studies are designed to investigate specific pathogens, either viruses or *Mycoplasma/Chlamydia*, with only a few studies designed to look more widely at aetiology. In these, the diagnostic yield has improved since 2000, with a pathogen identified in 65–86% of cases.^{26[II]28[Ib]32[Ib]29[Ib]} It is also apparent that a significant number of cases of CAP represent a mixed infection. The most comprehensive studies found a mixed viral-bacterial infection in 23–33% of cases.^{17[Ib]28[Ib]29[Ib]}

3.1.1 Which viruses are associated with CAP?

A number of viruses appear to be associated with CAP, the predominant one being RSV. RSV, parainfluenza and influenza are detected in similar proportions of children with pneumonia both in the community and in hospital.^{7[II]} Influenza virus was detected relatively infrequently in paediatric pneumonia using immunofluorescence.^{30[II]} However, with PCR techniques, influenza is found in 7–22% of cases.^{28[Ib]32[Ib]24[Ib]} In the UK during a 6-month winter influenza season, 16% of children with pneumonia had influenza A.^{31[II]} Other viruses isolated in children with pneumonia include adenovirus, rhinovirus, varicella zoster virus, cytomegalovirus, herpes simplex virus and enteroviruses.

Several new viruses have been identified and are regularly associated with pneumonia. Human metapneumovirus has been identified in 8–11.9% of cases.^{24[II]33[Ib]34[Ib]35[Ib]} and human bocavirus has recently been isolated from 4.5% in Thailand,^{36[Ib]} 14.2% in Spain^{24[Ib]} and 15.2% in Korea.^{33[Ib]} Coronavirus is identified in 1.5%^{33[Ib]} to 6.5% of cases.^{29[Ib]24[Ib]} Overall, viruses appear to account for 30–67% of CAP cases in childhood and are more frequently identified in children aged <1 year than in those aged >2 years (77% vs 59%).^{28[Ib]24[Ib]}

3.1.2 Which bacteria are associated with CAP?

Quantifying the proportion of CAP caused by bacteria is more difficult. *Streptococcus pneumoniae* is assumed to be the most common bacterial cause of CAP but is infrequently found in blood cultures. Overall, blood or pleural fluid culture of *S pneumoniae* is positive in 4–10% of cases of CAP.^{16[II]17[Ib]18[II]19[II]20[II]24[II]37[II]} It is commonly found in routine cultures of upper respiratory tract specimens, yet is known to be a commensal in this setting. A review of lung tap studies found 39% identified *S pneumoniae*.^{38[II]} A recent study of 34 children in Finland who had a lung aspirate identified *S pneumoniae* in 90% either by culture or PCR.^{39[II]} Pneumolysin-based PCR is increasingly used and validated.^{21[II]22[Ib]} Studies incorporating this into diagnosis in children not immunised with the conjugate PCV have detected *S pneumoniae* in around 44%,^{28[Ib]} often as a co-pathogen with either viruses or other bacteria. The proportion of CAP due to *S pneumoniae* increases up to 41% in cases where serological testing is used.^{29[Ib]} Mixed pneumococcal and viral infections appear important and are found in 62% of pneumococcal pneumonias.^{29[Ib]}

Pneumococcal serotypes are important, with serotypes 14, 6B, 19F and 23F being implicated more frequently in IPD and serotype 1 in empyema. The most common isolates in IPD since the introduction of PCV7 in Europe, including the UK, were serotypes 1, 19A, 3, 6A and 7E.^{40[Ib]} There are no UK data on the most frequent serotypes found in pneumonia, although serotype 1 has been predominantly responsible for empyema.^{41[Ib]} Recent data on serotypes identified in bacteraemic pneumonia in children from Italy since the introduction of PCV7 found serotypes 1 and 19A to be the most common.^{22[Ib]} Both these serotypes are included in PCV13, introduced into the UK immunisation schedule in 2010.

With the introduction of conjugate pneumococcal vaccines, indirect evidence of vaccine efficacy for the prevention of pneumonia can be used to assess the contribution of *S pneumoniae* to CAP. In children under 2 years, all trials have consistently shown a decrease in radiologically-confirmed pneumonia from 23% in the Philippines using PCV11^{42[Ib]} to 37% in the Gambia with PCV9^{43[Ib]} and 23.4% in California with PCV7.^{44[Ib]} The effect is most striking in the first year with a 32.2% reduction, and a 23.4% reduction in the first 2 years.^{44[Ib]} A recent study of PCV11 found that, although 34% of radiologically-confirmed

Table 4 Prospective studies of specific pathogens from developed countries

Reference [evidence level]	Age	Year and setting	Tests	Total episodes	Viral (n)	Bacteria, % (n)	Mycoplasma, % (n)	Chlamydia, % (n)	Mixed, % (n)	Total diagnosed, % (n)
Wojcik ²³ [Ib]	<5 years	ED	NPA hMPV PCR; NPfA	1296	RSV 23.1 hMPV 8.3 Adeno 3.4 Infl A 2.9 PIV 2.9					
Cilla ²⁴ [Ib]	1–35 months	2004–6, Spain, IP+OP	NPIA + PCR, BC, serology, Binax pleural fluid	338	67 (18 viral co-infection) RSV 19.8 HboV 14.2 RV 13.6 HMPV 11.5 Corona 6.5	Spn 2.1 (7)	1.8 (6)	*	NA	NA
Haman ²⁵ [II]	0–19 years	2005–6, Japan	NPA PCR	1700	27.9 (2.1% multiple) RV 14.5 RSV 9.4 hMPV 7.2 HboV 2.9	†	14.8 (251)	1.4 (24)	15.2	NA†
Don ²⁶ [II]	0.3–16 years	2001–2, Italy, IP+OP	Serology (viral and bacterial)	101	42 (3 dual) RSV 17 PIV 12 Infl 9 hMPV 5	44 Spn18 HI 3 Mcat 1	26.7 (27) <2 years: 1 2–5 years: 8 >5 years: 18 p<0.0001	7.9 (8)	20	65 (66)
Lin ²⁷ [III]	3 months–18 years	2001–2, Taiwan, IP	NPIA, NPVC; hMPV PCR; BC; urine Spn ag; serology MP+CP	116	38.8 (45) RSV 28.9 Adeno 28.9 hMPV 13.3 Infl 13.3	†	37.9 (44)	4.3 (5)	NA	NA†
Michelow ²⁸ [Ib]	6 weeks–18 years	1999–2000, USA, IP	NPIA, NPVC; Spn BPCR; BC; serology viral, Spn, MP, CP	154	45 (65) RSV 13 Infl 22 PIV 13 Adeno 7	60 (93) Spn 44 (68) GAS 1 (2) SA 1 (2)	14 (21)	9 (14)	23	79 (122)
Machereff ²⁹ [Ib]	2 months–5 years	2003–5, Switzerland; IP	NPIA + PCR; Spn BPCR; BC; serology viral, Spn, MP, CP;	99	67 RV 20h MPV 13 RSV 13 Infl 14 Parafli 13 Adeno 7 Corona 7	53 (52) Spn 46 (45) GAS 1 (1)	11	7	33 (33)	86 (85)
Drummond ³⁰ [II]	0–16 years	1996–8, UK, IP	NPIA; NPVC; serology viral, Spn, MP, CP; urine Spn ag;	136	37 (50) RSV 25 Infl A 5 CMV 3 Adeno 1.4	12.5 (17) GAS 7 (9) Spn 4 (5)	2 (3)		11 (15)	51 (70)
Laundy ³¹ [III]	0–5 years	2001–2, UK, IP+OP	NPIA + PCR; BC; specifically viral testing	51	43 (22) RSV 18 (9) Infl A 16 (8) Adeno 6 (3) PIV 6 (3)	12 (6) Spn 6	4 (2)	NA	NA	49 (25)

Continued

Table 4 Continued

Reference [evidence level]	Age	Year and setting	Tests	Total episodes	Viral (n)	Bacteria, % (n)	Mycoplasma, % (n)	Chlamydia, % (n)	Mixed, % (n)	Total diagnosed, % (n)
Tsolia ^{32(Ib)}	5–14 years	2004, Greece, IP	NPA PCR; serology MP, CP, Spn, HI, Mcat;	75	65 (49) RV 45 (34) Adeno 12 (9) PIV 8 (6) Infl 7 (5) RSV 3 (2) hMPV 1 (1)	40 (30) Spn 7 (5)	35 (26)	3 (2)	28 (21)	77 (58)

*No serological tests were performed for Chlamydia pneumoniae.

†All bacterial cases identified by NPA PCR so difficult to distinguish carriage from pathogen.

Adeno, adenovirus; ag, antigen; BC, blood culture; BPCR, blood PCR; Corona, coronavirus; CP, Chlamydia pneumoniae; ED, emergency department; GAS, group A streptococcus; HboV, human bocavirus; HI, Haemophilus influenzae; hMPV, human metapneumovirus; Infl, influenza A and B virus; IP, inpatients; Mcat, Moraxella catarrhalis; MP, mycoplasma; NA, not available; NPA PCR, nasopharyngeal PCR; NPIC, nasopharyngeal immunosay; NPVC, nasopharyngeal viral culture; OP, outpatients; PIV, parainfluenza virus 1–3; PC, pharyngeal culture; RSV, respiratory syncytial virus; RV, rhinovirus; Spn, Streptococcus pneumoniae.

pneumonias were prevented in children under 1 year, there was only a 2.7% decrease in those aged 12–23 months.^{42(Ib)} In children aged >2 years there was only a 9.1% reduction.^{44(Ib)} A Cochrane systematic review found a pooled vaccine efficacy for PCV11 of 27% for reduction of radiographically-confirmed pneumonia in children <2 years and 6% for clinical pneumonia.^{45(Ia)}

The introduction of PCV7 has dramatically decreased IPD due to vaccine serotypes in those countries where it has been universally introduced, but a steady increase in vaccine serotype replacement (ie, natural selection of pneumococcal serotypes not present in the vaccine) has been evident in the UK to 2010, so that the total IPD rate due to all serotypes is climbing back to similar rates before the introduction of PCV7 (<http://www.hpa.org.uk/HPA/Topics/InfectiousDiseases/InfectionsAZ/1203008863939/>). This trend is expected to reverse with the introduction of PCV13 (http://www.hpa.org.uk/web/HPAwebFile/HPAweb_C/1245581527892).

Other bacterial pathogens appear to be less frequent causes of CAP. Group A streptococcal infection is important in terms of severity as, when present, it is more likely to progress to paediatric ICU admission or empyema.^{30(II)46(III)} When looked for, it may be found in 1%^{28(Ib)29(Ib)} to 7% of cases.^{30(II)} It is increasingly associated with pneumonia complicated by empyema, as is *Staphylococcus aureus*.^{8(Ib)}

S aureus has also long been associated with increased mortality in influenza. Recent reports indicate a fivefold increase in influenza and *S aureus* mortality in children in the USA from 2004 to 2007.^{47(Ib)}

Claesson *et al*^{48(III)} assessed the antibody responses to non-capsulated *Haemophilus influenzae* and isolated it as the only pathogen from the nasopharynx of 43 of 336 children. A significant increase in IgG or IgM was shown in 16 (5% of all CAP). In the same study, 3% also had a significant increase in antibodies to *Moraxella catarrhalis*, suggesting that it too is an uncommon cause of CAP in children.^{49(II)} This was supported by another study by Korppi *et al*^{50(II)} in which seroconversion to *M catarrhalis* was documented in only 1.5% of cases of CAP.

3.1.3 What is the contribution of atypical organisms?

In aetiology studies, *Mycoplasma pneumoniae* previously accounted for 4–39% of isolates.⁵¹ Since 2000, those studies published where *M pneumoniae* is specifically sought in children admitted to hospital show remarkable consistency, with rates of detection from 27% to 36% (see table 5).^{52–56} Where *Chlamydia pneumoniae* is sought, it appears to be responsible for 5–14% of cases, but a single US study detected it in 27%.^{57(III)} Biases which need to be considered in these reports include whether children with mycoplasmal (or chlamydial) pneumonia are over-represented in hospital-based studies because of failure of penicillin-related antibiotic treatment in the community, or are over-represented in community studies because they are less sick and therefore less likely to be referred to hospital.

New bacteria are also being described. *Simkania negevensis*, a *Chlamydia*-like organism, is detected frequently by PCR in respiratory samples although antibody studies suggest it may be rarely implicated in pneumonia.^{58(III)59(III)}

3.2 Does the aetiology differ by age?

Several generalisations are possible with respect to age. With improved diagnostic tests including serology and PCR, evidence of specific aetiology tends to be more commonly found in younger children.^{26(II)28(Ib)24(Ib)} Michelow *et al*^{28(Ib)} detected a pathogen in 92% of children aged <6 months but in only 75%

Table 5 Aetiology studies looking for atypical organisms

Reference [evidence level]	Age	Year and Setting	Tests	Total episodes	Mycoplasma, % (n)	Chlamydia, % (n)	Mixed, % (n)
Kurz ⁵² [II]	2 months–18 years	2006–7, Austria, IP	NPA culture PCR serology	112		6.7 (4 of 60 tested)	
Principi ⁵³ [Ib]	2–14 years	1998–9, Italy, IP	Serology NPA PCR	418	35.8 (150)	11 (46)	6 (26)
Baer ⁵⁴ [II]	1–18 years	1999–2000, Switzerland, IP	Serology NPA PCR	50	32 (16) 1–3 years: 22% >3–7 years: 35% >7 years: 40%	8 (4)	6 (3)
Somer ⁵⁵ [II]	2 months–15 years	1996–8, Turkey, IP	Serology	140	27 (38)	5 (7)	?0
Korppi ⁵⁶ [II]	<15 years	1981–2, Finland, IP+OP	Serology (updated from previous study)	201	30 (61) 0–4 years: 9% 5–9 years: 40% 10–14 years: 67%	14 (29) 6% 13% 35%	5 (10)

IP, inpatients; NPA PCR, nasopharyngeal PCR; OP, outpatients.

of those aged >5 years. Although viral infections (especially RSV) are more commonly found in younger children,^{2[II]16[III]17[II]19[III]24[III]60[II]} bacteria are also isolated in up to 50% of children aged <2 years, together with a virus in up to half of these.^{28[IIb]} However, bacteria are more frequently identified with increasing age,^{28[IIb]} hence mixed infections become less frequent with age.^{26[II]61[II]} Vaccine probe studies indicate that one-third of young children with radiological changes have pneumococcal pneumonia,^{45[IIa]} with serological studies indicating at least 20% have a pneumococcal aetiology across all ages.^{26[III]} This has implications for the way in which we consider antibiotic choices.

Chlamydia and *Mycoplasma* species have been more commonly found in older children.^{16[III]19[III]26[III]52[III]54[III]60[III]62[III]63[III]64[II]} However, Block *et al*^{57[II]} found the incidence of *M pneumoniae* and *C pneumoniae* infections to be comparable in all age groups between 3 and 12 years. In particular, the finding of a 23% incidence of *M pneumoniae* infection and 23% of *C pneumoniae* infection in children aged 3–4 years is high. Recent studies have supported this, with Baer also noting a 22% incidence of *M pneumoniae* in children aged 1–3 years.^{54[II]} This raises questions about appropriate treatment in this age group, although young children may have milder *M pneumoniae* infection^{65[IVb]} and many recover without specific antibiotic treatment.^{66[II]}

Evidence statements

- ▶ *S pneumoniae* is the most common bacterial cause of pneumonia in childhood. [Ib]
- ▶ *S pneumoniae* causes about one-third of radiologically-confirmed pneumonia in children aged <2 years. [Ia]
- ▶ The introduction of PCV7 has dramatically decreased IPD due to vaccine serotypes in the UK, but a steady increase in vaccine serotype replacement is evident in the UK. [II]
- ▶ Pneumonia caused by group A streptococci and *S aureus* are more likely than pneumococcal to progress to the paediatric ICU or empyema. [III]
- ▶ Overall, viruses account for 30–67% of CAP cases in childhood and are more frequently identified in children aged <1 year than in those aged >2 years. [II]
- ▶ One-third of cases of CAP (8–40%) represent a mixed infection. [II]
- ▶ Mycoplasma is not unusual in children aged 1–5 years. [II]
- ▶ Age is a good predictor of the likely pathogens:
 - Viruses alone are found as a cause in younger children in up to 50%.
 - In older children, when a bacterial cause is found, it is most commonly *S pneumoniae* followed by mycoplasma and chlamydial pneumonia. [II]

4. CLINICAL FEATURES

4.1 How do children with CAP present?

Children with CAP may present with fever, tachypnoea, breathlessness or difficulty in breathing, cough, wheeze or chest pain. They may also present with abdominal pain and/or vomiting and may have headache. Children with upper respiratory tract infection and generalised wheeze with low-grade fever do not have pneumonia.

The clinical features of CAP vary with the age of the child (see table 6 and Section 6). Criteria for diagnosis based on signs and symptoms tend not to be very specific. Early work on diagnostic features was mainly undertaken in developing countries to assist non-healthcare workers in identifying the need for antibiotics or referral for hospital assessment in areas without access to radiology. Studies on pneumonia are often difficult to collate as the clinical settings and criteria for diagnosis can vary widely.

Clark *et al*^{20[II]} recently studied 711 children presenting to hospitals in the north-east of England with a history or signs of lower respiratory tract infection. Only children seen by a hospital paediatrician with radiographically-confirmed pneumonia were studied.

This study confirms the importance of respiratory rate as a valuable sign, as there was a significant correlation between respiratory rate and oxygen saturation ($r=-28$, $p<0.001$). This supports previous findings. In infants aged <1 year, a respiratory rate of 70 breaths/min had a sensitivity of 63% and specificity of 89% for hypoxaemia.^{68[II]}

Previously, Palafox *et al*^{69[II]} found that, in children aged <5 years, the WHO definitions for tachypnoea (respiratory rate >60 breaths/min for infants <2 months, >50 breaths/min in children aged 2–12 months and >40 breaths/min in children >12 months) had the highest sensitivity (74%) and specificity (67%) for radiographically-defined pneumonia. Interestingly, the respiratory rate was less sensitive and less specific in the first 3 days of illness. The respiratory rate was also significantly higher in patients with breathlessness or difficulty breathing ($p<0.001$). Significantly lower oxygen saturation was seen in children of all ages with increased work of breathing. Respiratory rate is of some value, but work of breathing is more indicative of the likelihood of pneumonia.

It is worth noting that prolonged fever associated with influenza should raise the possibility of pneumonia due to secondary bacterial infection.^{70[II]}

4.2 Are there clinical features that are associated with radiological changes of pneumonia?

In previous studies in infants, chest indrawing and/or a respiratory rate of >50 breaths/min gave a positive predictive value of 45% for radiological consolidation and a negative predictive

value of 83%.^{71[II]} In children aged >3 years, tachypnoea and chest recession or indrawing were not sensitive signs. Children can have pneumonia with respiratory rates of <40 breaths/min.^{72[III]} Crackles and bronchial breathing have been reported to have a sensitivity of 75% and specificity of 57%.^{68[III]}

An emergency room prospective study of 510 children aged 2–59 months identified similar clinical findings significantly associated with chest radiographic infiltrates as follows:

- ▶ age >12 months (adjusted OR 1.4, 95% CI 1.1 to 1.9);
- ▶ respiratory rate \geq 50 breaths/min (adjusted OR 3.5, 95% CI 1.6 to 7.5);
- ▶ oxygen saturation \leq 96% (adjusted OR 4.6, 95% CI 2.3 to 9.2); and
- ▶ in infants aged \leq 12 months, nasal flaring (adjusted OR 2.2, 95% CI 1.2 to 4.0).^{73[IIb]}

It must be noted that these features are also likely to be associated with children with viral-induced wheeze where radiographic changes do not represent pneumonia.

4.3. Can clinical features distinguish between viral, bacterial and atypical pneumonias?

Many studies—largely retrospective reviews and one small prospective study—have sought clinical features which might help to direct treatment options. These studies have confirmed previous evidence that there is no way of reliably distinguishing clinically (or radiologically) between aetiological agents.^{74[II]75[II]76[IVb]77[III]} This is complicated by mixed infections, the reported incidence of which varies from 8.2% to 23%.^{28[IIb]}

4.4. Are there specific clinical features associated with individual causative agents?

4.4.1 Pneumococcal pneumonia

Pneumococcal pneumonia starts with fever and tachypnoea. Cough is not a feature initially as alveoli have few cough receptors. It is not until lysis occurs and debris irritates cough receptors in the airways that cough begins.

Many studies therefore emphasise the importance of the history of fever and breathlessness and the signs of tachypnoea, indrawing and ‘toxic’ or ‘unwell’ appearance.

4.4.2 Mycoplasma pneumonia

Mycoplasma pneumonia can present with cough, chest pain and be accompanied by wheezing. Classically, the symptoms are worse than the signs would suggest. Non-respiratory symptoms, such as arthralgia and headache, might also suggest mycoplasma infection.^{78[IVb]}

A study of 154 children by Michelow *et al*.^{28[IIb]} found that, as has been proposed more recently, preschool children are just as likely as those of school age to have atypical pneumonia. There are likely to be geographical variations in these findings.

4.4.3 Staphylococcal pneumonia

This is indistinguishable from pneumococcal pneumonia at the beginning of the illness. It remains rare in developed countries where it is usually a disease of infants. It can complicate influenza in infants and older children. The incidence is increasing.

Evidence statements

- ▶ Children with CAP may present with fever, tachypnoea, breathlessness or difficulty in breathing, cough, wheeze or chest pain. These clinical features of CAP vary with the age of the child and tend not to be very specific for diagnosis. [IVb]
- ▶ In children older than 3 years, a history of difficulty breathing is an additional valuable symptom. [II]
- ▶ A raised respiratory rate is associated with hypoxaemia. [II]

Recommendation

- ▶ Bacterial pneumonia should be considered in children when there is persistent or repetitive fever >38.5°C together with chest recession and a raised respiratory rate. [D]

5. RADIOLOGICAL, GENERAL AND MICROBIOLOGICAL INVESTIGATIONS

5.1 When should a chest x-ray be performed?

The National Institute for Health and Clinical Excellence (NICE) has recently produced a guideline for the assessment of febrile illness in children which gives comprehensive advice on when radiographs should and should not be done in febrile children.⁷⁹

The recommendation of the guideline development group relevant to pneumonia is:

- ▶ Children with symptoms and signs suggesting pneumonia who are not admitted to hospital should not routinely have a chest x-ray.

Several other studies have also examined the relationship between radiographic findings and clinical pneumonia.

A prospective cohort study^{73[IIb]} of 510 patients in the USA sought to elucidate clinical variables that could be used to identify children likely to have radiographic pneumonia in an effort to spare unnecessary radiography in children without pneumonia. Radiographic pneumonia was defined as confluent opacification without volume loss, peripheral rather than central opacification and pleural effusion. Hyperinflation, increased peribronchial markings or subsegmental (band-like) atelectasis were not considered evidence of pneumonia. Forty-four of 510 cases (8.6%) had radiographic evidence of pneumonia. The clinical features thought to be more significantly associated with radiographic evidence of pneumonia have been discussed in Section 4.2.

Evidence from 1848 x-rays taken as part of a double-blind prospective randomised controlled trial^{80[IIb]} based at six centres in Pakistan in which children were diagnosed with non-severe pneumonia (and treated with antibiotics) based on the WHO criteria of tachypnoea without ‘danger symptoms’, showed that a radiological diagnosis of pneumonia was present in 14% (263/1848) with 26 (approximately 1%) of these constituting lobar pneumonia. Two hundred and twenty-three were classified as having ‘interstitial parenchymal changes’. Eighty-two per cent of x-rays were classified as normal and 4% were classified as ‘bronchiolitis’. Of those with radiographic evidence of pneumonia, 96% had fever, 99% had cough and 89% had difficulty breathing. Of those without radiographic evidence of pneumonia, 94% had fever, 99% had cough and 91% had difficulty breathing. From this study it would appear that there is poor agreement between clinical signs and chest radiography.

Other studies^{81[II]} have drawn similar conclusions. In an ambulatory setting, chest x-rays did not improve outcome.⁸²

5.1.1 Should a lateral x-ray be performed?

In a retrospective study of 1268 cases (7608 x-ray interpretations),^{83[III]} frontal and lateral chest x-rays of patients referred from an emergency department in the USA were reviewed by three radiologists independently. The sensitivity and specificity of the frontal x-ray alone for lobar consolidation was 100%. For non-lobe infiltrates the sensitivity was 85% and the specificity 98%, suggesting that these types of radiographic changes may be underdiagnosed in 15% of cases. The authors admit that some of the loss of sensitivity may be due to the wide variability in what is considered radiographic pneumonia. The clinical implications of these radiographically underdiagnosed pneumonias are not evident from the study.

Lateral x-rays are not routinely performed in paediatric CAP and the recommendation is that they are not necessary^{84[II]} and would mean exposing the child to further radiation.

5.1.2 How good is agreement on interpretation of x-rays?

There is great intra- and inter-observer variation in radiographic features used for diagnosing CAP. The WHO⁸⁵ produced a method for standardising the interpretation of chest x-rays in children for epidemiological purposes but, even using this scheme, the concordance rate between two trained reviewers was only 48% (250/521).

5.1.3 Can chest radiography be used to distinguish aetiology?

It is common in clinical practice that alveolar infiltration is thought to be secondary to a bacterial cause and bilateral diffuse interstitial infiltrates to atypical bacterial or viral infections. Adequate sensitivity is lacking for either of these assignments. Chest radiography is generally unhelpful for deciding on a potential causative agent.

Toikka *et al*^{86[II]} studied 126 patients, all of whom had x-rays. Bacterial aetiology was established in 54%, viral in 32% and 14% had unknown aetiology. The x-rays were divided into two groups by three radiologists unaware of the clinical diagnoses and characteristics: group 1 (n=61) had mild or moderate changes (interstitial infiltrations not covering a whole lung, minor alveolar infiltrations, hyperaeration, perihilar pneumonia) and group 2 (n=61) had marked changes (interstitial changes covering a whole lung, major alveolar infiltrations, lobar alveolar infiltrations, pleural fluid, abscess formation, atelectasis). Of those in group 1, 39% had bacterial pneumonia and 45% viral pneumonia. Of those in group 2, 69% had bacterial pneumonia and 18% viral pneumonia. Clearly, some bacterial infections are only mild, producing less marked changes on the chest x-rays and, conversely, some viral infections are severe, producing marked changes on the x-ray. Aetiology is therefore difficult to assign on the basis of the x-ray.

Virkki *et al*^{87[II]} studied 254 children with radiographically diagnosed CAP, assigning aetiology in 215/254 patients. Radiographic findings were classified as alveolar and/or interstitial pneumonia, hyperaeration, hilar enlargement, atelectasis, pleural fluid and location in one or both lungs. Of 137 children (64%) with alveolar infiltrates, 71% had evidence of bacterial infection; 72% of 134 cases with bacterial pneumonia had alveolar infiltrates and 49% with viral pneumonia had alveolar infiltrates. Half of those with interstitial infiltrates had bacterial infection. The sensitivity for bacterial infection in those with alveolar infiltrates was 0.72 and specificity was 0.51. For viral pneumonia with interstitial infiltrates the sensitivity was 0.49 and specificity 0.72.

In a prospective study of 136 children, Drummond *et al*^{80[II]} showed that there was no significant difference in aetiology among the five radiographic groups into which their cases were divided (lobar consolidation, patchy consolidation, increased perihilar and peribronchial markings, pneumonitis and effusion).

In a study of 101 Italian children with radiographically-defined pneumonia, Korppi *et al*^{77[II]} found no association between radiographic appearances and aetiology. Alveolar infiltrates were present in 44 children (62%). In those aged >5 years alveolar infiltrates were present in 68%, although blood cultures were negative in all cases. Alveolar infiltrates were present in 46% of those with viral aetiology, 67% with pneumococcal aetiology and 70% in each of those with atypical bacterial and unknown aetiologies.

Chest x-rays are often done in research studies of CAP, but these studies do not support the routine use of chest x-rays in the investigation and management of CAP.

5.1.4 Are follow-up x-rays necessary?

Two recent studies have examined the utility of follow-up x-rays in previously healthy children with CAP.

Virkki *et al*^{88[II]} published the results of a 3-year prospective study of 196 children with CAP. They also followed the children up at 8–10 years after diagnosis. Of 196 follow-up x-rays, there were abnormalities in 30% (infiltrates 67%, atelectasis 47%, lymph nodes 28%); 20% were new abnormalities. No change in management was instituted on the basis of these radiographic findings. Follow-up at 8–10 years of 194 patients showed no new illnesses associated with the previous pneumonia. In those with an uneventful recovery, x-rays are unnecessary.

Suren *et al*^{89[III]} published the results of a retrospective study of 245 children recovering from CAP. Of these, 133 had follow-up x-rays, 106 of which were normal and 27 of which were abnormal. Of the 106 patients with normal follow-up x-rays, two went on to develop further clinical problems (both recurrent pneumonias with no established underlying cause). Of the 27 patients with abnormal x-rays, three developed further clinical problems that could be related to the previous pneumonia. Of 112 who did not have follow-up x-rays, 10 developed subsequent clinical problems. Most of these occurred within the first 4 weeks after discharge, before the regular scheduling of the follow-up x-ray. The authors established that a follow-up x-ray might have been helpful in 5/245 cases. These modest benefits should be balanced against the exposure of children to radiation.

Evidence statements

- ▶ Chest radiography is too insensitive to establish whether CAP is of viral or bacterial aetiology. [II]

Recommendations

- ▶ Chest radiography should not be considered a routine investigation in children thought to have CAP. [A–]
- ▶ Children with signs and symptoms of pneumonia who are not admitted to hospital should not have a chest x-ray. [A–]
- ▶ A lateral x-ray should not be performed routinely. [B–]
- ▶ Follow-up radiography is not required in those who were previously healthy and who are recovering well, but should be considered in those with a round pneumonia, collapse or persisting symptoms. [B+]

5.2 What general investigations should be done in a child with suspected CAP in the community?

There is no indication for any tests in a child with suspected pneumonia in the community. Again, the recent guidance published by NICE regarding the management of feverish illness in children provides a useful framework for assessing these patients (see Section 5.1).

5.3 What general investigations should be done in a child with CAP who comes to hospital?

5.3.1 Pulse oximetry

Oxygen saturation measurements provide a non-invasive estimate of arterial oxygenation. The oximeter is easy to use and requires no calibration. It does require a pulsatile signal from the patient and is susceptible to motion artefacts. The emitting and receiving diodes need to be carefully opposed. To obtain a reliable reading:

- ▶ the child should be still and quiet;
- ▶ a good pulse signal should be obtained;

- ▶ once a signal is obtained, the saturation reading should be watched over at least 30 s and a value recorded once an adequate stable trace is obtained.

In a prospective study from Zambia, the risk of death from pneumonia was significantly increased when hypoxaemia was present.^{68[II]}

5.3.2 Acute phase reactants

Several studies have looked at using various acute phase reactants as a means of differentiating the aetiology and/or severity of CAP.^{64[II]86[III]90[III]91[III]92[III]93[III]} The utility of procalcitonin (PCT), cytokines, C reactive protein (CRP), erythrocyte sedimentation rate (ESR) and white blood cell (WBC) count individually and in combination has been assessed.

Korppi *et al*^{64[II]} examined WBC, CRP, ESR and PCT levels and chest radiographic findings in 132 cases in an effort to find combinations of markers that would differentiate a pneumococcal from a viral aetiology. For a combination of CRP >80 mg/l, WBC >17×10⁹/l, PCT >0.8 µg/l and ESR >63 mm/h, they found the likelihood ratio of the pneumonia being pneumococcal was 1.74 with a sensitivity of 61% and specificity of 65%. If alveolar infiltrates on the x-ray were included, the likelihood ratio was 1.89, specificity 82% and sensitivity 34%. None of these combinations of parameters was sufficiently sensitive or specific to differentiate bacterial (specifically pneumococcal) from viral pneumonia.

Michelow *et al*^{93[III]} investigated a panel of 15 cytokines in 55 patients with CAP. Forty-three children had an aetiological diagnosis. Twenty-one children had *S pneumoniae*, 17 had *M pneumoniae*, 11 had influenza A, three had *C pneumoniae*, one had *S aureus* and eight had viruses identified. Eleven had mixed viral and bacterial infections. Of the cytokines, interleukin 6 (IL-6) was the only one significantly associated with a rise in white cell band forms, PCT levels and unequivocal consolidation on the x-ray. However, there was no correlation with aetiology. There remains little evidence that cytokine profiles have any clinical utility.

Don *et al*^{91[III]} evaluated the usefulness of PCT for assessing both the severity and aetiology of CAP in a study of 100 patients. The cases were assigned into four aetiological groups: pneumococcal (n=18), atypical bacterial (n=25), viral (n=23) and unknown (n=34). There was no significant association between PCT levels and aetiological group. PCT levels were found to be significantly associated with severity of CAP, as defined by admission to hospital and the presence of alveolar infiltrates on the chest x-ray. Median PCT values (25th–75th centiles) for inpatients and outpatients, respectively, were 17.81 and 0.72.

Korppi *et al*^{90[III]} published a prospective population-based study of 190 children in an ambulatory primary care setting with radiologically-diagnosed pneumonia and aetiological diagnoses for five bacteria and seven viruses. They found that no association between severity of CAP (as defined by inpatient versus outpatient management) and PCT or between aetiology of CAP and PCT. The median values for each of the four aetiological groups (pneumococcal, mycoplasma/chlamydial, viral and unknown) were not significantly different (p=0.083). For inpatient versus outpatient management, PCT levels were 0.42 and 0.45 µg/l, respectively (p=0.77).

According to these two studies, there may be some alignment between PCT levels and severity, as defined by admission to hospital, but the evidence is still lacking for the ability of PCT to discriminate between viral and bacterial causes of CAP.

Toikka *et al*^{86[III]} studied 126 children with CAP, measuring PCT, CRP and IL-6 levels. Aetiology was established for six bacteria and 11 viruses; 54% had bacterial infection, 32% viral and 14% unknown. Median PCT and CRP levels were found to be significantly different, but there was marked overlapping of values. There were no significant differences for IL-6 levels. The sensitivity and specificity of CRP and PCT levels were low. If PCT, CRP and IL-6 levels are very high, then bacterial pneumonia is more likely but, generally, they have little value in differentiating viral from bacterial CAP.

Flood *et al*^{94[IIa]} performed a meta-analysis of eight studies, including several revealed in our recent search,^{87[III]95[III]96[III]} that examined the use of CRP in establishing aetiology in CAP. The pooled study population was 1230; 41% had bacterial CAP. A CRP range of 35–60 mg/l was significantly associated with bacterial pneumonia, producing an OR for bacterial versus non-bacterial CAP of 2.58 (95% CI 1.20 to 5.55). Given the prevalence of bacterial pneumonia of 41%, the positive predictive value for CRP values of 40–60 mg/l was 64%. The conclusion of the meta-analysis was that CRP was only weakly predictive for bacterial pneumonia.

Recommendations

- ▶ Acute phase reactants are not of clinical utility in distinguishing viral from bacterial infections and should not routinely be tested. [A–]
- ▶ CRP is not useful in the management of uncomplicated pneumonia. [A+]

5.4 What microbiological investigations should be performed?

Determining the causative agent in acute lower respiratory tract infection can be frustrating and difficult. The gold standard would be a sample directly from the infected region of lung (lung puncture). In the developed world, less invasive sampling methods are usually used to achieve a diagnosis.

5.4.1 Are there any microbiological investigations that should be performed in the community?

There is no indication for microbiological investigations to be done in the community. Some workers have investigated the feasibility of performing PCR analysis for viruses in nasopharyngeal secretions in the context of pandemic respiratory virus infections,^{97[III]} but this is not currently practical in the UK.

5.4.2 Which microbiological investigations should be performed on a child admitted to hospital?

It is important to attempt microbiological diagnosis in patients admitted to hospital with pneumonia severe enough to require admission to the paediatric ICU or with complications of CAP. They should not be considered routinely in those with milder disease.

Microbiological methods that may be used are several and include: blood culture, nasopharyngeal secretions and nasal swabs for viral detection (by PCR or immunofluorescence), acute and convalescent serology for respiratory viruses, *M pneumoniae* and *C pneumoniae* and, if present, pleural fluid for microscopy, culture, pneumococcal antigen detection and/or PCR.

Cevy-Macherel *et al*^{29[IIb]} identified a causative agent in 86% of 99 patients using a variety of microbiological, serological and biochemical means; 19% were of bacterial aetiology alone, 33% of viral aetiology alone and 33% of mixed viral and bacterial aetiology.

5.4.3 Which investigations are helpful in identifying a bacterial cause?

Blood culture

Positivity is often quoted as <10% in CAP.^{29[1b]} Pneumococcal pneumonia is seldom a bacteraemic illness. *S pneumoniae* is cultured in the blood in <5% of cases of pneumococcal CAP cases.^{98[IVb]}

Nasopharyngeal bacterial culture

This is uninformative. The presence of bacteria in the nasopharynx is not indicative of lower respiratory tract infection. Normal bacterial flora, as well as bacteria known to cause CAP, are often identified.^{29[1b]}

Pleural fluid

Pleural fluid cultures often show no growth, with just 9% of 47 cultures positive in a UK study.^{41[1b]} Most children will have received antibiotics for some time before aspiration of pleural fluid, which may explain why culture is so often uninformative. In this study, 32 of the 47 cultures were positive for pneumococcal DNA by PCR, whereas pneumococcal latex agglutination antigen testing was positive in 12, all of which were accounted for by PCR. Other studies have confirmed some utility for pneumococcal antigen detection in pleural fluid, identifying 27/29 empyemas in one study,^{99[III]} and with an apparently useful sensitivity of 90% and specificity of 95% compared with culture and/or PCR in another study.^{100[1b]}

Biochemical and immunological methods

Serum. A review of pneumococcal serology in childhood respiratory infections⁹⁸ concluded that pneumococcal antibody and immune complex assays, while sufficiently sensitive and specific for the detection of pneumococcal infections in children, were too complex for routine clinical use. Several other serological techniques exist and have been used in combinations with other culture and non-culture techniques to increase diagnostic yield. Paired serology seems to have the best yield.^{29[1b]30[III]}

Urine. Rapid detection of the capsular polysaccharide (CPS) antigen of *S pneumoniae* has shown promise for excluding pneumococcal infection. A study undertaken in France identified both a sensitivity and negative predictive value of 100% for an immunochromatographic test for CPS. However, specificity was too low to be clinically useful.^{101[1b]}

Rajalakshmi *et al*^{102[1b]} studied the efficacy of antigen detection assays of pneumolysin versus CPS antigen in urine. The rationale behind this study is that there is cross reactivity between antigens of *Viridans streptococci* and CPS, whereas pneumolysin is a protein produced only by *S pneumoniae*. The cases in this study were diagnosed by clinical and radiological evidence with blood culture positivity in 29.5%. The sensitivities of CPS and pneumolysin in urine when compared with blood culture were identical (52.3%), whereas the specificities were 61.2% for pneumolysin and 67.3% for CPS. Pneumolysin was detected in urine in 37.1–42.9% of cases compared with 2.1% of controls. CPS was detected in 38.6% of cases and was not detected in any controls. The negative predictive value of pneumolysin was 77.2% and of CPS was 76.7%.

PCR. Pneumolysin-based PCR is increasingly used to detect pneumococcus in blood, pleural fluid and secretions. Some studies have found good sensitivity (100%) and specificity (95%) in children with pneumonia,^{21[1b]103[III]} but others have been concerned about its specificity, especially in young children.^{104[III]} The laboratory techniques in this area are rapidly evolving and improving and show promise in helping to make microbiological diagnoses.

5.4.4 Which investigations are helpful for identifying atypical bacteria?

Paired serology (rising titres in antibody complement fixation tests) remains the mainstay for diagnosing *M pneumoniae* and *C pneumoniae* infections. However, two studies have investigated the use of PCR in identifying atypical bacterial infections.

Michelow *et al*^{103[III]} used PCR to diagnose *M pneumoniae* from nasopharyngeal and oropharyngeal swabs. They compared 21 children with serologically-proven *M pneumoniae* infections with 42 controls; 12 of the 21 children (57%) were PCR positive, 9 of the 12 each positive on nasopharyngeal and oropharyngeal samples, six on both. The greatest diagnostic yield was therefore when samples from both sites were combined and analysed. One of the controls was PCR positive. The OR for detecting *M pneumoniae* by PCR in serologically-proven cases was 54.7 (range 5.9–1279.3). When compared with ELISA, PCR had a sensitivity of 57.1%, specificity of 97.6%, positive predictive value of 97.3% and negative predictive value of 82.0%. The authors argue that PCR positivity for *M pneumoniae* in the upper respiratory tract is suggestive of lower respiratory tract infection. Of interest, in their study PCR-positive cases had a significantly longer duration of oxygen therapy (1.7 vs 0.78 days, $p=0.045$).

Maltezou *et al*^{105[III]} used PCR to diagnose *Legionella* and *Mycoplasma* lower respiratory tract infections by collecting serum and sputum or throat swabs. Of 65 children, serology (IgM EIA) was positive in 18 (27.5%) for *M pneumoniae* and in one (1.5%) for *Legionella*. Eleven of the 18 were diagnosed in the acute phase and nine (50%) of those serologically diagnosed were positive for *M pneumoniae* by PCR of sputum. Taken together, 15/18 were diagnosed by PCR and IgM serology; 3/18 were diagnosed by convalescent serology. The sensitivity of PCR versus IgM EIA in this study was 50%. This is consistent with recent observations that PCR can detect persistent *M pneumoniae* infection up to 7 months after disease onset.^{106[III]}

5.4.5 Which investigations are useful in identifying viral pneumonia?

Viruses are significant causes of paediatric CAP, either on their own or in mixed infections. Several studies have looked at the various techniques available for identifying viruses. These include viral culture, antigen detection, serology and PCR.

In the previously mentioned study undertaken by Cevey-Macherel and colleagues,^{29[1b]} they found viral PCR of nasopharyngeal aspirates to be very sensitive. In their study, 66/99 children had evidence of acute viral infection (33/99 as co-infection with bacteria). In those with a negative PCR, viral infection could not be detected by any other method. As well as viral culture and PCR, they used viral antigen detection and serum complement fixation tests.

Shetty *et al*^{107[1b]} subjected 1069 nasopharyngeal swabs to viral culture and direct fluorescent antibody (DFA) staining; 190 were DFA and viral culture positive (true positive) and 837 were DFA and culture negative (true negative). The sensitivity for DFA in this study was 84%, specificity 99%, positive predictive value 96% and negative predictive value 96%. One hundred and twenty of 140 hospitalised patients (86%) had viral cultures that reported positive only after the children had been discharged. The authors make the point that the viral cultures were not of any utility in making clinical management decisions.

Lambert^{97[III]} collected nose-throat swabs and nasopharyngeal aspirates in 295 patients (303 illnesses) and subjected them to PCR analysis for eight common respiratory viruses. Nose-throat swabs are thought to be 'less invasive' samples that are more easily collected by parents and therefore of possible benefit in rapid diagnosis in the context of a respiratory virus pandemic. In

186/303 (61%) paired nose-throat swabs/nasopharyngeal aspirates, at least one virus was detected. For nose-throat swabs the sensitivity was 91.9% for RSV and 93.1% for influenza A. For adenovirus, the sensitivity of nose-throat swabs was 65.9% (95% CI 50.1% to 79.5%) compared with 93.2% (95% CI 81.3% to 98.6%) for nasopharyngeal aspirates. Concordance between nasopharyngeal aspirates and nose-throat swabs was 89.1%. The authors argue that the combination of PCR and the less invasive nose-throat swabs provides adequate sensitivity for the detection of respiratory viruses.

Evidence statements

- ▶ Blood culture positivity is uncommon. [Ib]
- ▶ Urinary antigen detection may be helpful as negative predictors of pneumococcal infection in older children. Positive tests are too non-specific and may represent carriage. [Ib]
- ▶ Molecular methods have shown promise but are currently most useful in identifying viral pathogens. [Ib]

Recommendations

- ▶ Microbiological diagnosis should be attempted in children with severe pneumonia sufficient to require paediatric intensive care admission or those with complications of CAP. [C]
- ▶ Microbiological investigations should not be considered routinely in those with milder disease or those treated in the community. [C]
- ▶ Microbiological methods used should include:
 - Blood culture. [C]
 - Nasopharyngeal secretions and/or nasal swabs for viral detection by PCR and/or immunofluorescence. [C]
 - Acute and convalescent serology for respiratory viruses, *Mycoplasma* and *Chlamydia*. [B+]
 - If present, pleural fluid should be sent for microscopy, culture, pneumococcal antigen detection and/or PCR. [C]
- ▶ Urinary pneumococcal antigen detection should not be done in young children. [C]

6. SEVERITY ASSESSMENT

6.1 Why is severity assessment important?

Children with CAP may present with a range of symptoms and signs: fever, tachypnoea, breathlessness, difficulty in breathing, cough, wheeze, headache, abdominal pain and chest pain (see Section 4). The spectrum of severity of CAP can be mild to severe (see table 6). Infants and children with mild to moderate respiratory symptoms can be managed safely in the community.^[IVb]

The most important decision in the management of CAP is whether to treat the child in the community or refer and admit for hospital-based care. This decision is best informed by an accurate assessment of severity of illness at presentation and an assessment of likely prognosis. In previously well children there is a low risk of complications and treatment in the community is preferable. This has the potential to reduce inappropriate hospital admissions and the associated morbidity and costs.

Management in these environments is dependent on an assessment of severity. Severity assessment will influence microbiological investigations, initial antimicrobial therapy, route of administration, duration of treatment and level of nursing and medical care.

6.2. What are the indications for referral and admission to hospital?

A referral to hospital will usually take place when a general practitioner assesses a child and feels the clinical severity

Table 6 Severity assessment

	Mild to moderate	Severe
Infants	Temperature <38.5°C Respiratory rate <50 breaths/min Mild recession Taking full feeds	Temperature >38.5°C Respiratory rate >70 breaths/min Moderate to severe recession Nasal flaring Cyanosis Intermittent apnoea Grunting respiration Not feeding Tachycardia* Capillary refill time ≥2 s
Older children	Temperature <38.5°C Respiratory rate <50 breaths/min Mild breathlessness No vomiting	Temperature >38.5°C Respiratory rate >50 breaths/min Severe difficulty in breathing Nasal flaring Cyanosis Grunting respiration Signs of dehydration Tachycardia* Capillary refill time ≥2 s

*Values to define tachycardia vary with age and with temperature.^{67[II]}

requires admission. In addition to assessing severity, the decision whether to refer to hospital or not should take account of any underlying risk factors the child may have together with the ability of the parents/carers to manage the illness in the community. This decision may be influenced by the level of parental anxiety.

Children with CAP may also access hospital services when the parents/carers bring the child directly to a hospital emergency department. In these circumstances hospital doctors may come across children with mild disease that can be managed in the community. Some with severe disease will require hospital admission for treatment. One key indication for admission to hospital is hypoxaemia. In a study carried out in the developing world, children with low oxygen saturations were shown to be at greater risk of death than adequately oxygenated children.^{68[III]} The same study showed that a respiratory rate of ≥70 breaths/min in infants aged <1 year was a significant predictor of hypoxaemia.

There is no single validated severity scoring system to guide the decision on when to refer for hospital care. An emergency care-based study assessed vital signs as a tool for identifying children at risk from a severe infection. Features including a temperature >39°C, saturations <94%, tachycardia and capillary refill time >2 s were more likely to occur in severe infections.^{108[II]} Auscultation revealing absent breath sounds with a dull percussion note should raise the possibility of a pneumonia complication by effusion and should trigger a referral to hospital.^{109[III]110[III]} There is some evidence that an additional useful assessment is the quality of a child's cry and response to their parent's stimulation^{111[II]}; if these are felt to be abnormal and present with other worrying features, they may also strengthen the case for referral for admission to hospital.

A global assessment of clinical severity and risk factors is crucial in identifying the child likely to require hospital admission.

Features of severe disease in an infant include:

- ▶ oxygen saturation <92%, cyanosis;
- ▶ respiratory rate >70 breaths/min;

- ▶ significant tachycardia for level of fever (values to define tachycardia vary with age and with temperature^{67[III]});
 - ▶ prolonged central capillary refill time >2 s;
 - ▶ difficulty in breathing;
 - ▶ intermittent apnoea, grunting;
 - ▶ not feeding;
 - ▶ chronic conditions (eg, congenital heart disease, chronic lung disease of prematurity, chronic respiratory conditions leading to infection such as cystic fibrosis, bronchiectasis, immune deficiency).
- Features of severe disease in an older child include:
- ▶ oxygen saturation <92%, cyanosis;
 - ▶ respiratory rate >50 breaths/min;
 - ▶ significant tachycardia for level of fever (values to define tachycardia vary with age and with temperature^{67[III]});
 - ▶ prolonged central capillary refill time >2 s;
 - ▶ difficulty in breathing;
 - ▶ grunting;
 - ▶ signs of dehydration;
 - ▶ chronic conditions (eg, congenital heart disease, chronic lung disease of prematurity, chronic respiratory conditions leading to infection such as cystic fibrosis, bronchiectasis, immune deficiency).

6.3 What are the indications for transfer to intensive care?

There are two main scenarios when a child is likely to need admission to an intensive care unit: (1) when the pneumonia is so severe that the child is developing severe respiratory failure requiring assisted ventilation; and (2) a pneumonia complicated by septicaemia. Key features that suggest a child requires transfer include:

- ▶ failure to maintain oxygen saturation >92% in fractional inspired oxygen of >0.6; [IVb]
- ▶ shock; [IVb]
- ▶ rising respiratory and pulse rate with clinical evidence of severe respiratory distress and exhaustion, with or without a raised arterial carbon dioxide tension; [IVb]
- ▶ recurrent apnoea or slow irregular breathing. [IVb]

6.4 When should the child be reassessed?

For children with CAP, reassessment is important, whether in the community or in hospital.

In the community, after treatment for CAP has been initiated (eg, oral antibiotics plus advice on antipyretics and hydration), parents/carers should be advised on what symptoms and signs to look for when reassessing their child. Looking for the features in the following three areas may be useful in identifying cases where the infection is not being adequately treated and reassessment by a doctor is required:

- ▶ Fever: a high swinging or persistent fever (the temperature should start to settle 48 h after treatment starts). [IVb]
- ▶ Effort of breathing: the child seems to be working harder to breathe with a fast breathing rate and chest recession. [IVb]
- ▶ Effect of breathing: the child is not comfortable and relaxed but is agitated and distressed. [IVb]

In hospital, all the above should be assessed in addition to vital signs. Medical assessment should always look for signs of overwhelming infection and septicaemia, for pleural collections that may develop into empyema thoracis^{110[III]} and for signs of dehydration. A prolonged fever is a useful pointer to empyema developing,^{112[III]} and this may require drainage for successful treatment.¹¹³ Less common complications should also be considered (see Section 9).

Evidence statements

- ▶ Children with CAP present with a range of symptoms and signs. A global assessment of clinical severity and risk factors is crucial in identifying the child likely to require hospital admission. [IVb]

Recommendations

- ▶ For a child in the community, re-consultation to the general practitioner with persistent fever or parental concern about fever should prompt consideration of CAP. [D]
- ▶ Children with CAP in the community or in hospital should be reassessed if symptoms persist and/or they are not responding to treatment. [D]
- ▶ Children who have oxygen saturations <92% should be referred to hospital for assessment and management. [B+]
- ▶ Auscultation revealing absent breath sounds with a dull percussion note should raise the possibility of a pneumonia complication by effusion and should trigger a referral to hospital. [B-]
- ▶ A child in hospital should be reassessed medically if there is persistence of fever 48 h after initiation of treatment, increased work of breathing or if the child is becoming distressed or agitated. [D]

7. GENERAL MANAGEMENT IN THE COMMUNITY AND IN HOSPITAL

7.1 What general management strategy should be provided for a child treated in the community?

The general management of a child who does not require hospital referral comprises advising parents and carers about:

- ▶ management of fever
 - use of antipyretics
 - avoidance of tepid sponging
- ▶ preventing dehydration
- ▶ identifying signs of deterioration
- ▶ identifying signs of other serious illness
- ▶ how to access further healthcare (providing a ‘safety net’). The ‘safety net’ should be one or more of the following:
 - ▶ provide the parent or carer with verbal and/or written information on warning symptoms and how further healthcare can be accessed;
 - ▶ arrange a follow-up appointment at a certain time and place;
 - ▶ liaise with other healthcare professionals, including out-of-hours providers, to ensure the parent/carers has direct access to a further assessment for their child.

Recommendation

- ▶ Families of children who are well enough to be cared for at home should be given information on managing fever, preventing dehydration and identifying any deterioration. [D]

7.1.1 Over-the-counter remedies

No over-the-counter cough medicines have been found to be effective in pneumonia.^{114[1a]}

7.2 What is the general management for children cared for in hospital?

7.2.1 Oxygen therapy

Hypoxic infants and children may not appear cyanosed. Agitation may be an indicator of hypoxia.

Patients whose oxygen saturation is <92% while breathing air should be treated with oxygen given by nasal cannulae, head box or face mask to maintain oxygen saturation >92%.^{68[II]}

There is no strong evidence to indicate that any one of these methods of oxygen delivery is more effective than any other. A study comparing the different methods in children aged <5 years concluded that the head box and nasal cannulae are equally effective,^{115[III]} but the numbers studied were small and definitive recommendations cannot be drawn from this study. It is easier to feed with nasal cannulae. Alternative methods of delivering high-flow humidified nasal oxygen are available and increasingly used. Higher concentrations of humidified oxygen can also be delivered via face mask or head box if necessary.

Where the child's nose is blocked with secretions, gentle suctioning of the nostrils may help. No studies assessing the effectiveness of nasopharyngeal suction were identified.

No new published studies about oxygen therapy were identified in the update searches.

Evidence statement

- ▶ Agitation may be an indicator that a child is hypoxic. [IVb]

Recommendation

- ▶ Patients whose oxygen saturation is $\leq 92\%$ while breathing air should be treated with oxygen given by nasal cannulae, high-flow delivery device, head box or face mask to maintain oxygen saturation $>92\%$. [B]

7.2.2 Fluid therapy

Children who are unable to maintain their fluid intake due to breathlessness or fatigue need fluid therapy. Studies on preterm infants or infants weighing <2000 g have shown that the presence of a nasogastric tube compromises respiratory status.^{116[III]117[IVb]} Older children may be similarly affected, although potentially to a lesser extent because of their larger nasal passages so, although tube feeds offer nutritional benefits over intravenous fluids, they should be avoided in severely ill children. Where nasogastric tube feeds are used, the smallest tube should be passed down the smaller nostril.^{117[IVb]} There is no evidence that nasogastric feeds given continuously are any better tolerated than bolus feeds (no studies were identified); however, in theory, smaller more frequent feeds are less likely to cause stress to the respiratory system.

Patients who are vomiting or who are severely ill may require intravenous fluids and electrolyte monitoring. Attention is drawn to the 2007 National Patient Safety Agency alert 'Reducing the risk of hyponatraemia when administering intravenous fluids to children'.¹¹⁸ Serum levels of sodium can be low in children with pneumonia and there is debate as to whether this is related to inappropriate antidiuretic hormone secretion or overall sodium depletion. Good quality evidence is lacking.

Recommendations

- ▶ Nasogastric tubes may compromise breathing and should therefore be avoided in severely ill children and especially in infants with small nasal passages. If use cannot be avoided, the smallest tube should be passed down the smallest nostril. [D]
- ▶ Plasma sodium, potassium, urea and/or creatinine should be measured at baseline and at least daily when on intravenous fluids. [C]

7.2.3 Physiotherapy

Two randomised controlled trials^{119[Ib]120[II]} and an observational study^{121[Ib]} conducted on adults and children showed that physiotherapy did not have any effect on the length of hospital

stay, fever or chest radiographic findings in patients with pneumonia. There is no evidence to support the use of physiotherapy, including postural drainage, percussion of the chest or deep breathing exercises.^{119[Ib]120[II]122[IVb]} There is a suggestion that physiotherapy is counterproductive, with patients who receive physiotherapy being at risk of having a longer duration of fever than the control group.^{119[Ib]} In addition, there is no evidence to show that physiotherapy is beneficial in the resolving stage of pneumonia.

A supported sitting position may help to expand the lungs and improve respiratory symptoms in children with respiratory distress.

There were no new studies identified.

A summary article^{121[Ib]} summarised the studies discussed above.

Recommendation

- ▶ Chest physiotherapy is not beneficial and should not be performed in children with pneumonia. [A–]

8. ANTIBIOTIC MANAGEMENT

8.1 Introduction

The management of a child with CAP involves a number of decisions regarding treatment with antibiotics:

- ▶ whether to treat with antibiotics;
- ▶ which antibiotic and by which route;
- ▶ when to change to oral treatment if intravenous treatment initiated;
- ▶ duration of treatment.

The British Thoracic Society guidelines of 2002⁵¹ found scanty evidence with which to address these questions. Trials comparing various different antibiotic combinations found little differences in efficacy, one trial indicating equivalence of intramuscular penicillin and oral amoxicillin in children with pneumonia treated in the emergency department,^{123[Ib]} and no evidence to inform parenteral to oral switch or duration of antibiotics. Since then, a number of large studies from many different countries have attempted to address some of these issues. There are, however, some difficulties in assessing their relevance to the UK as children have been enrolled from developing and developed countries with different criteria used as definitions for pneumonia and with different immunisation backgrounds, circulating bacteria and resistance patterns.

8.2 Which children should be treated with antibiotics?

One of the major problems in deciding whether to treat a child with CAP with antibiotics is the difficulty in distinguishing bacterial pneumonia (which would benefit from antibiotics) from non-bacterial pneumonia (which would not). This difficulty has been described in Section 3. Resistance to antibiotics among bacterial pathogens is increasing and is of concern; an important factor in this increase is the overuse of antibiotics.

Two studies were identified in which children with diagnosed respiratory infections treated with antibiotics were compared with a group not treated with antibiotics.^{124[II]126[II]} However, both enrolled many children who, in the UK, would have bronchiolitis not pneumonia. One was a randomised controlled trial of 136 young Danish children aged 1 month to 6 years, either with pneumonia or bronchiolitis, with 84% RSV positive. Severe disease was excluded. There were no differences in the course of the illness between the two groups (ampicillin or penicillin treated or placebo), although 15 of the 64 in the placebo group did eventually receive antibiotics.^{124[II]} The other

in India enrolled children aged 2–59 months with cough, rapid breathing or difficulty breathing, audible or auscultatory wheeze, non-response to bronchodilator without chest radiographic changes. There was a non-significant difference in failure rate of 24% with placebo and 19.9% with amoxicillin for 3 days.^{126[III]} Unfortunately, as most children in these studies appeared to have bronchiolitis rather than pneumonia, it is not possible to draw conclusions from them regarding whether young children with pneumonia benefit from antibiotics.

The other way of approaching this is relating knowledge of aetiology in specific ages to the likelihood that these will be effective. Both viruses and bacteria are found in young children, with vaccine probe studies suggesting that one-third of children aged <2 years with radiological signs have pneumococcal pneumonia.^{44[IIb]45[IIa]} However, in those with a clinical diagnosis of pneumonia, this falls to 6%.^{45[IIa]} With the introduction into the UK primary immunisation schedule of PCV7 in 2006 and of PCV13 in April 2010, the likelihood of bacterial pneumonia in a fully vaccinated young child is therefore very small.

Recommendations

- ▶ All children with a clear clinical diagnosis of pneumonia should receive antibiotics as bacterial and viral pneumonia cannot be reliably distinguished from each other. [C]
- ▶ Children aged <2 years presenting with mild symptoms of lower respiratory tract infection do not usually have pneumonia and need not be treated with antibiotics but should be reviewed if symptoms persist. A history of conjugate pneumococcal vaccination gives greater confidence to this decision. [C]

8.3 How much of a problem is antibiotic resistance?

Antibiotic resistance has the potential to impact on therapeutic choices and there is worldwide concern about increasing antibiotic resistance among pneumococci and its potential impact on the treatment of pneumonia and invasive pneumococcal disease.

8.3.1 *Streptococcus pneumoniae*

Despite the rapid reduction in PCV7 serotypes following the introduction of conjugate vaccine in 2000, penicillin resistance increased steadily in Cleveland, USA until 2003–4. At this time, 51% of isolates were non-susceptible to penicillin.^{127[IIb]}

PCVs have reduced drug-resistant *S pneumoniae* but, because of increased intermediate resistance among non-PCV7 serotypes, reductions in intermediate penicillin-resistant strains have not followed. Serotype 19A, which is both antibiotic resistant and a common cause of disease, is not covered by PCV7 and is now increasing worldwide, including in countries without PCV7.^{128[IIa]129[IIa]130[IIa]} However, it is included within PCV 13, the introduction of which would potentially prevent a further 50% of continuing IPD in children.

S pneumoniae macrolide resistance is also increasing, and different mechanisms of resistance drive different levels of resistance. High-level resistance also involves clindamycin resistance, whereas low-level resistance only involves macrolides. Resistance mechanisms vary geographically with mostly low-level resistance in the USA but high-level resistance in Europe.^{131[IIa]} US surveillance data for 2000–4 of respiratory isolates indicate a stable 30% are macrolide resistant, although an increasing proportion has high-level macrolide resistance.^{132[IIb]}

A study from Portugal significantly associated macrolide use with the increase of penicillin and erythromycin non-susceptible

isolates from adults ($p < 0.01$) and erythromycin non-susceptible isolates among children ($p = 0.006$).^{133[IIb]}

In the UK, however, penicillin resistance is far less prevalent. Pneumococcal penicillin non-susceptibility in pneumococci causing bacteraemia rose in the 1990s to 6.7% in 2000 and has since declined to around 4% in 2007. Geographical variation ranges from 1.5% in the East Midlands to 8.0% in London. This is in contrast to much of mainland Europe where rates are 25–50% in France and Spain.^{134[IIb]} Erythromycin resistance in the UK is higher at 9.3% in 2007, but has decreased since 2004 and also varies across the country from 5.2% in north-east England to 14.7% in London. It is much higher in mainland Europe with 25–50% macrolide resistance in France and Italy.^{134[IIb]} In 2006–7, erythromycin resistance was found in 12% of invasive isolates from children, with serotype 19A still very uncommon.^{135[IIb]}

8.3.2 Group A streptococcus

There is also varying prevalence of macrolide resistance in *Streptococcus pyogenes* (group A streptococcus) worldwide, in some areas up to 40%,^{136[IIb]} and β -lactamase production in *H influenzae* is widespread. Overall, in the UK the reported resistance rates for group A streptococcus to clindamycin, erythromycin and tetracycline were 5.1%, 5.6% and 14.0% respectively in 2007, with 4.4% resistant to all three. Penicillin resistance has not been seen to date and penicillin remains the therapeutic drug of choice.^{134[IIb]}

8.3.3 *Staphylococcus aureus*

Methicillin-resistant *S aureus* (MRSA) is of increasing concern in the USA and has been implicated in the increase in pleural empyemas seen.^{137[III]} Although MRSA contributes to 31% of *S aureus* bacteraemia in the UK,^{134[IIb]} it has not yet been a significant factor in either empyema or pneumonia.^{30[II]41[III]138[III]}

8.3.4 What is the clinical impact of antibiotic resistance?

The management of pneumococcal infections has been challenged by the development of resistance and, more recently, the unexpected spread of resistant clones of serotypes such as 19A following the introduction of a conjugate PCV for use in children in 2000.

Despite the increasingly wide literature on antibiotic resistance, there is less evidence of the impact of this on clinical outcomes for children. However, series of children with pneumonia from the USA^{139[III]} and South Africa^{140[III]} found no difference in outcome between penicillin-resistant or sensitive pneumococcal pneumonias, nor were differences noted in children with pleural empyema and sensitive or resistant pneumococcal disease in terms of duration of fever and tachypnoea, need for surgical treatment, bacteraemia incidence, mean duration of therapy or length of hospital stay.^{141[III]}

Outcomes in pneumococcal meningitis have not been shown to differ significantly between susceptible and resistant isolates.^{142[III]}

In the face of no widespread failure of antibiotic therapy, high-dose penicillin G (ie, in severe infection double the normal dose, as recommended in the *British National Formulary for Children*), other β lactams and many other agents continue to be efficacious parenterally for pneumonia and bacteraemia.^{130[III]}

Increased macrolide use is associated with pneumococcal and group A streptococcal resistance^{133[IIb]} and bacteria may acquire macrolide resistance very fast if used indiscriminately.^{143[IIb]} However, the clinical impact of macrolide resistance is unclear, with case reports describing clinical failure in adults with

bacteraemic infection^{144[III]} but not in those with pneumonia.^{145[III]146[III]} To date, no association with resistance and treatment failure has been demonstrated in children.

8.4 Which antibiotic should be used?

It is clear that there is variation in medical prescribing that largely reflects custom, local practice and availability. We have reviewed the relevant scientific evidence and provide recommendations based, where possible, on that evidence, but more frequently recommendations are based on judgements about what constitutes safe and effective treatment. In pneumonia in children, the nature of the infecting organism is almost never known at the initiation of treatment and the choice of antibiotic is therefore determined by the reported prevalence of different pathogens at different ages, knowledge of resistance patterns of expected pathogens circulating within the community and the immunisation status of the child.

Randomised controlled trials comparing different antibiotics have shown similar or equivalent efficacy variously for macrolides, amoxicillin, co-amoxiclav, cefaclor, erythromycin, cefixime, cefpodoxime, cefuroxime and ceftriaxone.^{19[II]63[II]147[II]148[II]149[II]150[II]151[II]152[II]} Additionally, newer antibiotics such as levofloxacin^{153[II]} have shown efficacy in similar studies in the USA. Despite pharmacological differences in oral cephalosporins (cefaclor has an association with skin reactions but, compared with cefalexin, good activity against *S pyogenes* and *S pneumoniae*; cefixime is poorly active against *S aureus* and cefuroxime axetil has poor oral absorption), no differences in clinical efficacy have been identified. There also appears to be little difference between different macrolides,^{57[II]154[II]155[II]} although clarithromycin may be better tolerated than erythromycin.^{156[II]}

A Cochrane review of antibiotics in childhood pneumonia in 2006 was updated in 2010.^{157[IIa]} Twenty-seven studies were reviewed, encompassing 11 928 children, comparing multiple antibiotics. However, most of these were enrolled on the basis of WHO-defined clinical criteria for pneumonia and were from developing countries. It is recognised that 82% of children identified clinically who fulfil the WHO criteria for pneumonia have normal chest x-rays.^{158[IIb]} Five studies were from high income developed countries and less than a quarter enrolled using chest radiographic definitions. Findings included equivalence for amoxicillin and macrolides (azithromycin and clarithromycin), procaine penicillin and cefuroxime. On the basis of single studies, co-amoxiclav was comparable to azithromycin and cefpodoxime but superior to amoxicillin.

High-dose amoxicillin twice daily is a pharmacokinetically satisfactory dosing regime and may aid compliance^{159[IIb]} although, in Pakistan, outcomes for infants aged 2–59 months with non-severe outpatient-treated clinical pneumonia were the same with standard and double dose amoxicillin.^{160[IIb]}

In adults, macrolide antibiotics have been shown to reduce the length and severity of pneumonia caused by *M pneumoniae* compared with penicillin or no antibiotic treatment.¹⁶¹ In an experimental mouse model of respiratory *M pneumoniae* infection, clarithromycin significantly decreased *M pneumoniae* levels and cytokines compared with placebo.^{162[II]} There is little evidence for specific antibiotics in children.

Improved short- and long-term outcomes have been described in children with respiratory tract infections (a mixture of upper and lower by clinical diagnosis) treated with macrolides compared with those not treated.^{66[II]} Of those children with lower respiratory tract infections due to *M pneumoniae* and/or *C pneumoniae* assessed as 'clinical failures', 83% had not been

treated with macrolides.^{53[II]} Children with *M pneumoniae* pneumonia in Taiwan had significantly shorter duration of fever if treated with macrolides.^{163[II]} However, a Cochrane review of specific mycoplasma treatment in children with lower respiratory tract infections did not find enough evidence to indicate whether antibiotics improved outcomes in children with *M pneumoniae* lower respiratory tract infections, although they suggested that the study by Esposito *et al* indicated that some children may benefit.^{164[IIVa]}

A recent report of a closed audit loop showed that prescribing can be rationalised to simple narrow spectrum antibiotics (eg, intravenous benzylpenicillin or oral penicillin V) with the introduction of a local management protocol. This has the potential to reduce the likelihood of antibiotic resistance developing.^{138[II]}

Information on the antibiotics recommended for treatment of CAP is available in the *British National Formulary for Children*.

Evidence statement

- ▶ Although there appears to be no difference in response to conventional antibiotic treatment in children with penicillin-resistant *S pneumoniae*, the data are limited and the majority of children in these studies were not treated with oral β -lactam agents alone. [III]

Recommendations

- ▶ Amoxicillin is recommended as first choice for oral antibiotic therapy in all children because it is effective against the majority of pathogens which cause CAP in this group, is well tolerated and cheap. Alternatives are co-amoxiclav, cefaclor, erythromycin, azithromycin and clarithromycin. [B]
- ▶ Macrolide antibiotics may be added at any age if there is no response to first-line empirical therapy. [D]
- ▶ Macrolide antibiotics should be used if either mycoplasma or chlamydia pneumonia is suspected or in very severe disease. [D]
- ▶ In pneumonia associated with influenza, co-amoxiclav is recommended. [D]

8.5 How should antibiotics be given?

One large adequately-powered trial compared the efficacy of treatment with intramuscular penicillin (one dose) and oral amoxicillin given for 24–36 h to children with pneumonia treated in the emergency department.^{123[IIb]} Evaluation at 24–36 h did not show any differences in outcome between the groups.

Oral amoxicillin has been shown to be as effective as parenteral penicillin, even in severe pneumonia, in the UK, Africa/Asia and Pakistan.^{158[IIb]165[IIb]166[IIb]} The PIVOT trial^{166[IIb]} randomised UK children over the age of 6 months admitted to hospital with pneumonia to either oral amoxicillin or intravenous penicillin. Only the most severe were excluded (oxygen saturation <85%, shock, pleural effusion requiring drainage). The antibiotics produced equivalent outcomes.

A large multicentre randomised open-label equivalency study in eight developing countries in Africa, Asia and South America enrolled 1702 infants aged 3–59 months with severe clinically-defined pneumonia and randomised them to oral amoxicillin or parenteral penicillin. Identical outcomes were obtained in each group, with 19% treatment failure.^{165[IIb]}

In a randomised control trial a group in Pakistan also studied severe pneumonia and compared home treatment using twice daily oral high-dose amoxicillin with parenteral ampicillin, with equivalent results in both groups.^{158[IIb]}

Two of these were reviewed in a Cochrane review^{167[1a]} which concluded that oral therapy was a safe and effective alternative to parenteral treatment, even in severe disease in hospitalised children.

Parenteral administration of antibiotics in children (which, in the UK, is generally intravenous) is traumatic as it requires the insertion of a cannula, drug costs are much greater than with oral regimens and admission to hospital is generally required. However, in the severely ill child, parenteral administration ensures that high concentrations are achieved rapidly in the lung. The parenteral route should also be used if there are concerns about oral absorption.

Recommendations

- ▶ Antibiotics administered orally are safe and effective for children presenting with even severe CAP. [A+]
- ▶ Intravenous antibiotics should be used in the treatment of pneumonia in children when the child is unable to tolerate oral fluids or absorb oral antibiotics (eg, because of vomiting) or presents with signs of septicaemia or complicated pneumonia. [D]
- ▶ Recommended intravenous antibiotics for severe pneumonia include amoxicillin, co-amoxiclav, cefuroxime, and cefotaxime or ceftriaxone. These can be rationalised if a microbiological diagnosis is made. [D]

8.6 When should antibiotics be switched from parenteral to oral?

No randomised controlled trials were identified that addressed the issue of when it is safe and effective to transfer from intravenous to oral antibiotic therapy. There can thus be no rigid statement about the timing of transfer to oral treatment and this is an area for further investigation.

Recommendation

- ▶ In a patient who is receiving intravenous antibiotic therapy for the treatment of CAP, oral treatment should be considered if there is clear evidence of improvement. [D]

8.7 What is the optimal duration of antibiotic treatment?

Since 2000 there have been a few trials and a Cochrane review comparing the duration of antibiotic treatments.^{168[II]} All are from developing countries, except for a trial from Finland which randomised children with pneumonia (a high proportion of which had a bacterial cause) to either 4 or 7 days of parenteral penicillin or cefuroxime, with no difference in outcome.^{150[1b]}

Three randomised trials of short-course oral antibiotics, only two of which are published,^{125[II]169[III]} were reviewed in a Cochrane review by Haider *et al.*^{168[II]} These studies enrolled infants in developing countries with WHO-defined clinical criteria of non-severe pneumonia to either 3 or 5 days treatment with oral amoxicillin. No difference was seen in acute cure or relapse rates between the groups. There are some difficulties in translating these data as the cohorts of infants included many who would be defined as having bronchiolitis with wheeze (13% with wheeze and 23% RSV-positive in the paper by Agarwal *et al.*^{125[II]}; 23% with wheeze and 18% RSV-positive in the paper by Qazi *et al.*^{169[III]}). Some had simple upper respiratory tract infections as, although 99% had a cough, only 38% had difficulty breathing and 80% had <10 breaths excess respiratory rate. Only 14% had chest radiographic changes.^{169[III]} Most of these children may not have needed antibiotics at all and, indeed, fall into the group that, if vaccinated, it is suggested do not require antibiotic treatment in the UK. It is therefore still not known whether a 3-day antibiotic course is sufficient to treat a child with a bacterial pneumonia.

9. COMPLICATIONS AND FAILURE TO IMPROVE

9.1 What factors should be considered in children who fail to improve?

If a child remains feverish or unwell 48 h after treatment has commenced, re-evaluation is necessary. Answers to the following questions should be sought:

- ▶ Is the patient having appropriate drug treatment at an adequate dosage?
- ▶ Is there a lung complication of pneumonia such as a collection of pleural fluid with the development of an empyema or evidence of a lung abscess?
- ▶ Is the patient not responding because of a complication in the host such as immunosuppression or coexistent disease such as cystic fibrosis?

There has been concern that the increased incidence of penicillin-resistant *S pneumoniae* would lead to failure of treatment. However, one study^{170[III]} has shown that there is no difference in the percentage of children in hospital treated successfully with penicillin or ampicillin when the organism was penicillin-susceptible or penicillin-resistant. The authors noted that the serum concentration of penicillin or ampicillin achieved with standard intravenous dosages was much greater than the minimum inhibitory concentration for most penicillin-resistant strains.

9.2 What are the common complications of CAP?

9.2.1 Pleural effusions and empyema

Parapneumonic effusions are thought to develop in 1% of patients with CAP^{171[III]} but, in those admitted to hospital, effusions may be found in as many as 40% of cases.^{172[III]} It has recently been reported that empyema thoracis may be increasing in incidence.^{173[III]174[III]} A persisting fever despite adequate antibiotic treatment should always lead the clinician to be suspicious of the development of empyema.^{174[III]} Fluid in the pleural space is revealed on the chest x-ray and the amount of fluid is best estimated by ultrasound examination. A clinician should consider empyema when a child has a persistent fever beyond 7 days^{174[III]} or a fever not settling after 48 h of antibiotics. Where an effusion is present and the patient is persistently feverish, the pleural space should be drained, ideally in a specialist centre.

There is debate as to the best method of draining effusions. More details on the diagnosis and management of empyema are given in the BTS guidelines on pleural disease in children.¹¹³

9.2.2 Necrotising pneumonias

Lung abscess, although a rare complication of CAP in children, is believed to be an increasing and important complication.^{175[III]176[III]} There are some data suggesting that some children are predisposed to this more severe form of lung infection. The predisposing factors include: congenital cysts, sequestrations, bronchiectasis, neurological disorders and immunodeficiency.^{177[III]} There are also emerging data that certain serotypes of pneumococcal disease are more likely to lead to necrotising pneumonia and abscess formation than others,^{175[III]} and that *S aureus* with Pantone–Valentine leukocidin toxin can lead to severe lung necrosis with a high risk of mortality.^{178[III]} Suspicion of abscess/necrosis is often raised on the chest x-ray and diagnosis can be confirmed by CT scanning.^{179[IVb]} Prolonged intravenous antibiotic courses may be required until the fever settles. Lung abscess with an associated empyema may be drained at decortication if the abscess is close to the parietal pleura and is large. Ultrasound- or CT-guided percutaneous drainage can be used.^{180[III]}

9.2.3 Septicaemia and metastatic infection

Children can present with symptoms and signs of pneumonia but also have features of systemic infection. Children with septicaemia and pneumonia are likely to require high dependency or intensive care management. Metastatic infection can rarely occur as a result of the septicaemia associated with pneumonia. Osteomyelitis or septic arthritis should be considered, particularly with *S aureus* infections.

9.2.4 Haemolytic uraemic syndrome

S pneumoniae is a rare cause of haemolytic uraemic syndrome. A recent case series found that, of 43 cases of pneumococcal haemolytic uraemic syndrome, 35 presented with pneumonia and 23 presented with empyema.^{181[III]} Although a rare complication, in cases with pallor, profound anaemia and anuria, this should be considered.

9.2.5 Long-term sequelae

Severe pneumonia, empyema and lung abscess can lead to long-term respiratory symptoms secondary to areas of fibrosis or bronchiectasis. Children with empyema and lung abscess should be followed up after discharge until they have recovered completely and their chest x-ray has returned to near normal. There are also prospective data to suggest that children who have had an episode of CAP are more likely to suffer from prolonged cough (19% vs 8%), chest wall shape abnormality (9% vs 2%) and also doctor-diagnosed asthma (23% vs 11%).^{41[16]} The majority of children with CAP have no long-term sequelae and make a complete recovery. However, this study does suggest that some children do develop persistent expiratory symptoms, especially if they have a pre-existing diagnosis of asthma. The reasons for this are as yet unclear, but it is advised to counsel parents and carers at discharge to consult their doctor if these symptoms occur.

9.3 Complications of specific infections

9.3.1 *Staphylococcus aureus* pneumonia

Pneumatoceles occasionally leading to pneumothorax are more commonly seen with *S aureus* pneumonia. The long-term outlook is good with normal lung function.^{182[III]183[III]} There has been an increase in MRSA and some severe cases reported requiring extracorporeal membrane oxygenation.^{184[III]} Pantone–Valentine leukocidin toxin-producing *S aureus* can lead to severe lung necrosis with a high risk of mortality.^{178[III]} In the UK and other developed countries, *S aureus* pneumonia is sufficiently unusual to warrant investigation of the child's immune system.

9.3.2 *Mycoplasma pneumoniae*

Complications in almost every body system have been reported in association with *M pneumoniae*. Rashes are common, the Stevens–Johnson syndrome occurs rarely, and haemolytic anaemia, polyarthritis, pancreatitis, hepatitis, pericarditis, myocarditis and neurological complications including encephalitis, aseptic meningitis, transverse myelitis and acute psychosis have all been reported.

9.3.3 *Streptococcus pneumoniae* pneumonia

Pneumococcus is the most common bacterium to cause CAP and the major complication of empyema thoracis. It is increasingly being found to cause necrotic pneumonia and abscess formation that is believed to be associated with certain serotypes.^{175[III]} Vaccination programmes against pneumococcus do not protect against all serotypes and surveillance studies monitoring for

shift in serotype prevalence are ongoing. The rare complication of haemolytic uraemic syndrome is described with pneumococcal pneumonia.

Recommendations

- ▶ If a child remains feverish or unwell 48 h after hospital admission with pneumonia, re-evaluation is necessary with consideration given to possible complications. [D]
- ▶ Children with severe pneumonia, empyema and lung abscess should be followed up after discharge until they have recovered completely and their chest x-ray has returned to near normal. [D]

10. PREVENTION AND VACCINATION

General improvements in public health over the last century have contributed greatly to the prevention of CAP. However, there is still more to be done in improving housing, reducing crowding, reducing smoking and improving the uptake of routine vaccines.

10.1 Would smoking cessation help?

A recent paper from the USA estimated the annual excess healthcare service use and expenditure for respiratory conditions in children linked to exposure to smoking in the home.^{185[III]} They linked data from the nationally representative Medical Expenditure Panel survey with the National Health Interview survey that has self-reported data on smoking inside the home. Data were obtained on 2759 children aged 0–4 years and respiratory health assessed in three groups (smoking inside the home on ≥ 1 day/week, smoking outside the home, no smoking) using multivariate analysis. Children exposed to smoking in the home had an increased likelihood of hospital admission (4.3% vs 1.1% had at least one hospital stay/year) and an increased likelihood of an emergency unit visit for respiratory illness (8.5% vs 3.6%). The data were not specific for pneumonia. Indoor smoking was associated with additional healthcare expenditure for respiratory conditions of US\$117 per child. Smoking cessation would decrease respiratory illness in children but there are no specific data for pneumonia.

10.2 What is the influence of vaccination?

Vaccination has made a real impact on pneumonia and child survival worldwide. The WHO estimates that, in 2003, more than 2 million deaths were averted by immunisation, of which 607 000 were prevented by the use of pertussis vaccination. Pneumonia contributes to 56–86% of all deaths attributed to measles. The introduction of measles vaccination resulted in a decrease of deaths from measles worldwide from 2.5 million/annum prior to 1980 to 345 000 in 2005.^{186[III]}

10.2.1 *Haemophilus influenzae*

The impact of Hib conjugate vaccine on pneumonia in the UK is not known, but a number of clinical trials and case–control studies from the developing world have established that the introduction of this vaccine reduced radiologically-confirmed pneumonia by 20–30%.^{187[1b]188[II]} The WHO estimated that the global incidence of *H influenzae* pneumonia in the absence of vaccination was 1304/100 000 children aged <5 years.^{189[1b]}

10.2.2 *Bordetella pertussis*

Whooping cough continues to be seen in the UK, with infants aged <6 months having the highest morbidity and mortality.^{190[III]} In the USA, from 1997 to 2000, 29 134 cases of pertussis were reported of whom 7203 were aged <6 months;

5.2% overall and 11.8% of those aged <6 months had pneumonia. There were 62 deaths, 56 (90%) of whom were aged <6 months.^{191[III]} Improved uptake of primary pertussis vaccination would help to prevent cases, but another important factor may be an increasing pool of susceptible older children and adults, which is why some countries have elected to have a booster vaccination programme in adolescence.^{190[III]}

10.2.3 *Streptococcus pneumoniae*

The introduction of conjugate PCVs has been the biggest recent change in pneumonia prevention. They have been hugely successful in decreasing IPD in children and there have been several studies of the effectiveness in decreasing respiratory morbidity. In the developed world, follow-up from the controlled trial of PCV7 in 37 868 children in the USA using the WHO standardisation for radiographic definition of pneumonia showed efficacy against a first episode of radiographically-confirmed pneumonia adjusting for age, gender and year of vaccination of 30.3% (95% CI 10.7% to 45.7%, $p=0.0043$) for per protocol vaccination.^{192[II]} Evidence that efficacy is sustained outwith a clinical trial comes from a time series analysis in the USA showing that, 4 years after the universal vaccination programme started, all-cause pneumonia admission rates in children aged <2 years had declined by 39% (95% CI 2% to 52%).^{193[III]} Similarly, three population-based pneumonia surveillance studies from US health maintenance organisations demonstrated fewer outpatient and emergency visits for pneumonia in children aged <2 years (a decrease of 19–33 per 1000 children per year),^{194[III]} a decrease of 6 (95% CI 5.4 to 6.7) per 1000 hospitalisations for all-cause pneumonia and a decrease of 40.8 (95% CI 38.8 to 42.7) per 1000 ambulatory visits in children aged <2 years,^{195[III]} and a significant 26% reduction in confirmed outpatient events for pneumonia in children aged <1 year.^{196[III]} A single-blind observational follow-up study of PCV7 in Italy also confirmed that radiologically-confirmed CAP was significantly less in the vaccinated group (RR 0.35; 95% CI 0.22 to 0.53).^{197[II]}

Introduction of the PCV7 conjugate vaccine in England and Wales in 2006 has almost abolished invasive disease caused by these pneumococcal serotypes in children <2 years and has substantially reduced the number in older children. However, there has been an increase in reports of invasive disease caused by non-vaccine serotypes.^{198[IVb]} A national time-trends study (1997–2008) recently published results on the impact of the PCV7 conjugate vaccination programme on childhood hospital admissions for bacterial pneumonia in the UK and showed a 19% decrease (RR 0.81; 95% CI 0.79 to 0.83) from 2006 to 2008.^{9[III]}

10.2.4 Influenza

The UK influenza vaccine programme for children is continually evolving following the H1N1 pandemic in 2009. There are no data of effectiveness in relation to childhood pneumonia in the UK. In Japan, analysis of all-age pneumonia mortality data suggested universal childhood vaccination offered population protection with prevention of one death for every 420 children vaccinated.^{199[III]} In Ontario, Canada the effects of introduction of a universal influenza immunisation programme were compared with targeted immunisation in other provinces.^{200[II]} After introduction, all-age mortality decreased more in Ontario than in other provinces, as did hospitalisations, emergency department visits and doctors' office visits in the paediatric age groups (<5 years and 5–19 years).

Evidence statements

- ▶ Vaccination has had a major impact on pneumonia and child mortality worldwide. [II]
- ▶ Conjugate pneumococcal vaccines decrease radiographically-confirmed pneumonia episodes in young children by around 30%. [Ib]

11. AUDIT CRITERIA

The British Thoracic Society Audit Programme includes an annual national paediatric pneumonia audit for children aged >12 months admitted with a final diagnostic coding label of pneumonia into a paediatric unit and under paediatric care. The audit tool will be updated to reflect the content of the current guideline in 2011.

Competing interests None.

Provenance and peer review Not commissioned; internally peer reviewed.

REFERENCES

1. **Lim WS**, Baudouin SV, George RC, *et al*. BTS guidelines for the management of community acquired pneumonia in adults: update 2009. *Thorax* 2009;**64**(Suppl 3): iii1–55.
2. **Korppi M**, Heiskanen-Kosma T, Jalonen E, *et al*. Aetiology of community-acquired pneumonia in children treated in hospital. *Eur J Pediatr* 1993;**152**:24–30.
3. **Senstad AC**, Suren P, Brauteset L, *et al*. Community-acquired pneumonia (CAP) in children in Oslo, Norway. *Acta Paediatr* 2009;**98**:332–6.
4. **Clark JE**, Hammal D, Hampton F, *et al*. Epidemiology of community-acquired pneumonia in children seen in hospital. *Epidemiol Infect* 2007;**135**:262–9.
5. **Weigl JA**, Puppe W, Belke O, *et al*. Population-based incidence of severe pneumonia in children in Kiel, Germany. *Klin Padiatr* 2005;**217**:211–19.
6. **Weigl JA**, Bader HM, Everding A, *et al*. Population-based burden of pneumonia before school entry in Schleswig-Holstein, Germany. *Eur J Pediatr* 2003;**162**:309–16.
7. **Forster J**, Ihorst G, Rieger CH, *et al*. Prospective population-based study of viral lower respiratory tract infections in children under 3 years of age (the PRI.DE study). *Eur J Pediatr* 2004;**163**:709–16.
8. **Grijalva CG**, Nuorti JP, Zhu Y, *et al*. Increasing incidence of empyema complicating childhood community-acquired pneumonia in the United States. *Clin Infect Dis* 2010;**50**:805–13.
9. **Koshy E**, Murray J, Bottle A, *et al*. Impact of the seven-valent pneumococcal conjugate vaccination (PCV7) programme on childhood hospital admissions for bacterial pneumonia and empyema in England: national time-trends study, 1997–2008. *Thorax* 2010;**65**:770–4.
10. **Canani RB**, Cirillo P, Roggero P, *et al*. Therapy with gastric acidity inhibitors increases the risk of acute gastroenteritis and community-acquired pneumonia in children. *Pediatrics* 2006;**117**:e817–20.
11. **Melegaro A**, Edmunds WJ, Pebody R, *et al*. The current burden of pneumococcal disease in England and Wales. *J Infect* 2006;**52**:37–48.
12. **Di Ciommo V**, Russo P, Attanasio E, *et al*. Clinical and economic outcomes of pneumonia in children: a longitudinal observational study in an Italian paediatric hospital. *J Eval Clin Pract* 2002;**8**:341–8.
13. **Ehiken B**, Ihorst G, Lippert B, *et al*. Economic impact of community-acquired and nosocomial lower respiratory tract infections in young children in Germany. *Eur J Pediatr* 2005;**164**:607–15.
14. **Shoham Y**, Dagan R, Givon-Lavi N, *et al*. Community-acquired pneumonia in children: quantifying the burden on patients and their families including decrease in quality of life. *Pediatrics* 2005;**115**:1213–19.
15. **Lorgelly PK**, Atkinson M, Lakhanpaul M, *et al*. Oral versus i.v. antibiotics for community-acquired pneumonia in children: a cost-minimisation analysis. *Eur Respir J* 2010;**35**:858–64.
16. **Claesson BA**, Trollfors B, Brolin I, *et al*. Etiology of community-acquired pneumonia in children based on antibody responses to bacterial and viral antigens. *Pediatr Infect Dis J* 1989;**8**:856–62.
17. **Juven T**, Mertsola J, Waris M, *et al*. Etiology of community-acquired pneumonia in 254 hospitalized children. *Pediatr Infect Dis J* 2000;**19**:293–8.
18. **Ruuskanen O**, Nohynek H, Ziegler T, *et al*. Pneumonia in childhood: etiology and response to antimicrobial therapy. *Eur J Clin Microbiol Infect Dis* 1992;**11**:217–23.
19. **Wubbel L**, Muniz L, Ahmed A, *et al*. Etiology and treatment of community-acquired pneumonia in ambulatory children. *Pediatr Infect Dis J* 1999;**18**:98–104.
20. **Clark JE**, Hammal D, Spencer D, *et al*. Children with pneumonia: how do they present and how are they managed? *Arch Dis Child* 2007;**92**:394–8.
21. **Michelow IC**, Lozano J, Olsen K, *et al*. Diagnosis of *Streptococcus pneumoniae* lower respiratory infection in hospitalized children by culture, polymerase chain reaction, serological testing, and urinary antigen detection. *Clin Infect Dis* 2002;**34**:E1–11.
22. **Resti M**, Moriondo M, Cortimiglia M, *et al*. Community-acquired bacteremic pneumococcal pneumonia in children: diagnosis and serotyping by real-time polymerase chain reaction using blood samples. *Clin Infect Dis* 2010;**51**:1042–9.

23. **Wolf DG**, Greenberg D, Shemer-Avni Y, *et al*. Association of human metapneumovirus with radiologically diagnosed community-acquired alveolar pneumonia in young children. *J Pediatr* 2010;**156**:115–20.
24. **Cilla G**, Onate E, Perez-Yarza EG, *et al*. Viruses in community-acquired pneumonia in children aged less than 3 years old: high rate of viral coinfection. *J Med Virol* 2008;**80**:1843–9.
25. **Hamano-Hasegawa K**, Morozumi M, Nakayama E, *et al*. Comprehensive detection of causative pathogens using real-time PCR to diagnose pediatric community-acquired pneumonia. *J Infect Chemother* 2008;**14**:424–32.
26. **Don M**, Fasoli L, Paldanius M, *et al*. Aetiology of community-acquired pneumonia: serological results of a paediatric survey. *Scand J Infect Dis* 2005;**37**:806–12.
27. **Lin PY**, Lin TY, Huang YC, *et al*. Human metapneumovirus and community-acquired pneumonia in children. *Chang Gung Med J* 2005;**28**:683–8.
28. **Michelow IC**, Olsen K, Lozano J, *et al*. Epidemiology and clinical characteristics of community-acquired pneumonia in hospitalized children. *Pediatrics* 2004;**113**:701–7.
29. **Cevey-Macherel M**, Galetto-Lacour A, Gervais A, *et al*. Etiology of community-acquired pneumonia in hospitalised children based on WHO clinical guidelines. *Eur J Pediatr* 2009;**168**:1429–36.
30. **Drummond P**, Clark J, Wheeler J, *et al*. Community acquired pneumonia—a prospective UK study. *Arch Dis Child* 2000;**83**:408–12.
31. **Laundy M**, Ajayi-Obe E, Hawrami K, *et al*. Influenza A community-acquired pneumonia in East London infants and young children. *Pediatr Infect Dis J* 2003;**22**:S223–7.
32. **Tsolia MN**, Psarras S, Bossios A, *et al*. Etiology of community-acquired pneumonia in hospitalized school-age children: evidence for high prevalence of viral infections. *Clin Infect Dis* 2004;**39**:681–6.
33. **Choi E**, Lee H, Kim S, *et al*. The association of newly identified respiratory viruses with lower respiratory tract infections in Korean children, 2000–2005. *Clin Infect Dis* 2006;**43**:585–92.
34. **Williams J**, Harris P, Tollefson S, *et al*. Human metapneumovirus and lower respiratory tract disease in otherwise healthy infants and children. *N Engl J Med* 2004;**350**:443–50.
35. **Wolf D**, Greenberg D, Kalkstein D, *et al*. Comparison of human metapneumovirus, respiratory syncytial virus and influenza A virus lower respiratory tract infections in hospitalised young children. *Pediatr Infect Dis J* 2006;**25**:320–4.
36. **Fry A**, Lu X, Chittaganpitch M, *et al*. Human bocavirus: a novel parvovirus epidemiologically associated with pneumonia requiring hospitalization in Thailand. *J Infect Dis* 2007;**195**:1038–45.
37. **Clements H**, Stephenson TJ. Blood culture is a poor method of confirming pneumococcus as cause of childhood pneumonia. *BMJ* 1996;**313**:757.
38. **Vuori-Holopainen E**, Peltola H. Reappraisal of lung tap: review of an old method for better etiologic diagnosis of childhood pneumonia. *Clin Infect Dis* 2001;**32**:715–26.
39. **Vuori-Holopainen E**, Salo E, Saxen H, *et al*. Etiological diagnosis of childhood pneumonia by use of transthoracic needle aspiration and modern microbiological methods.[comment]. *Clin Infect Dis* 2002;**34**:583–90.
40. **Isaacman DJ**, McIntosh ED, Reinert RR. Burden of invasive pneumococcal disease and serotype distribution among Streptococcus pneumoniae isolates in young children in Europe: impact of the 7-valent pneumococcal conjugate vaccine and considerations for future conjugate vaccines. *Int J Infect Dis* 2010;**14**:e197–209.
41. **Eastham KM**, Freeman R, Kearns AM, *et al*. Clinical features, aetiology and outcome of empyema in children in the north east of England. *Thorax* 2004;**59**:522–5.
42. **Lucero MG**, Nohynek H, Williams G, *et al*. Efficacy of an 11-valent pneumococcal conjugate vaccine against radiologically confirmed pneumonia among children less than 2 years of age in the Philippines: a randomized, double-blind, placebo-controlled trial. *Pediatr Infect Dis J* 2009;**28**:455–62.
43. **Cutts FT**, Zaman SM, Enwere G, *et al*. Efficacy of nine-valent pneumococcal conjugate vaccine against pneumonia and invasive pneumococcal disease in the Gambia: randomised, double-blind, placebo-controlled trial. *Lancet* 2005;**365**:1139–46.
44. **Black SB**, Shinefield HR, Ling S, *et al*. Effectiveness of heptavalent pneumococcal conjugate vaccine in children younger than five years of age for prevention of pneumonia. *Pediatr Infect Dis J* 2002;**21**:810–15.
45. **Lucero MG**, Dulalia VE, Nillos LT, *et al*. Pneumococcal conjugate vaccines for preventing vaccine-type invasive pneumococcal disease and x-ray defined pneumonia in children less than two years of age. *Cochrane Database Syst Rev* 2009;(4):CD004977.
46. **Al-Kaabi N**, Solh Z, Pacheco S, *et al*. A comparison of group A streptococcus versus Streptococcus pneumoniae pneumonia. *Pediatr Infect Dis J* 2006;**25**:1008–12.
47. **Finelli L**, Fiore A, Dhara R, *et al*. Influenza-associated pediatric mortality in the United States: increase of Staphylococcus aureus coinfection. *Pediatrics* 2008;**122**:805–11.
48. **Claesson BA**, Lagergard T, Trollfors B. Antibody response to outer membrane of noncapsulated Haemophilus influenzae isolated from the nasopharynx of children with pneumonia. *Pediatr Infect Dis J* 1991;**10**:104–8.
49. **Claesson BA**, Leinonen M. Moraxella catarrhalis: an uncommon cause of community-acquired pneumonia in Swedish children. *Scand J Infect Dis* 1994;**26**:399–402.
50. **Korppi M**, Katila ML, Jaaskelainen J, *et al*. Role of Moraxella (Branhamella) catarrhalis as a respiratory pathogen in children. *Acta Paediatr* 1992;**81**:993–6.
51. **British Thoracic Society of Standards of Care Committee**. BTS guidelines for the management of community acquired pneumonia in childhood. *Thorax* 2002;**57**:i1–24.
52. **Kurz H**, Gopfrich H, Wabnegger L, *et al*. Role of Chlamydia pneumoniae in children hospitalized for community-acquired pneumonia in Vienna, Austria. *Pediatr Pulmonol* 2009;**44**:873–6.
53. **Principi N**, Esposito S, Blasi F, *et al*. Role of Mycoplasma pneumoniae and Chlamydia pneumoniae in children with community-acquired lower respiratory tract infections. *Clin Infect Dis* 2001;**32**:1281–9.
54. **Baer G**, Engelcke G, Abele-Horn M, *et al*. Role of Chlamydia pneumoniae and Mycoplasma pneumoniae as causative agents of community-acquired pneumonia in hospitalised children and adolescents. *Eur J Clin Microbiol Infect Dis* 2003;**22**:742–5.
55. **Somer E**, Salman N, Yalcin I, *et al*. Role of Mycoplasma pneumoniae and Chlamydia pneumoniae in children with community-acquired pneumonia in Istanbul, Turkey. *J Trop Pediatr* 2006;**52**:173–8.
56. **Korppi M**, Heiskanen-Kosma T, Kleemola M. Incidence of community-acquired pneumonia in children caused by Mycoplasma pneumoniae: serological results of a prospective, population-based study in primary health care. *Respirology* 2004;**9**:109–14.
57. **Block S**, Hedrick J, Hammerschlag MR, *et al*. Mycoplasma pneumoniae and Chlamydia pneumoniae in pediatric community-acquired pneumonia: comparative efficacy and safety of clarithromycin vs. erythromycin ethylsuccinate. *Pediatr Infect Dis J* 1995;**14**:471–7.
58. **Heiskanen-Kosma T**, Paldanius M, Korppi M. Simkania negevensis may be a true cause of community acquired pneumonia in children. *Scand J Infect Dis* 2008;**40**:127–30.
59. **Fasoli L**, Paldanius M, Don M, *et al*. Simkania negevensis in community-acquired pneumonia in Italian children. *Scand J Infect Dis* 2008;**40**:269–72.
60. **Heiskanen-Kosma T**, Korppi M, Jokinen C, *et al*. Etiology of childhood pneumonia: serologic results of a prospective, population-based study. *Pediatr Infect Dis J* 1998;**17**:986–91.
61. **Korppi M**. Mixed microbial aetiology of community-acquired pneumonia in children. *APMIS* 2002;**110**:515–22.
62. **Gendrel D**, Raymond J, Moulin F, *et al*. Etiology and response to antibiotic therapy of community-acquired pneumonia in French children. *Eur J Clin Microbiol Infect* 1997;**16**:388–91.
63. **Harris JA**, Kolokathis A, Campbell M, *et al*. Safety and efficacy of azithromycin in the treatment of community-acquired pneumonia in children. *Pediatr Infect Dis J* 1998;**17**:865–71.
64. **Korppi M**. Non-specific host response markers in the differentiation between pneumococcal and viral pneumonia: what is the most accurate combination? *Pediatr Int* 2004;**46**:545–50.
65. **Lee KY**. Pediatric respiratory infections by Mycoplasma pneumoniae. *Expert Rev Anti Infect Ther* 2008;**6**:509–21.
66. **Esposito S**, Bosis S, Faelli N, *et al*. Role of atypical bacteria and azithromycin therapy for children with recurrent respiratory tract infections. *Pediatr Infect Dis J* 2005;**24**:438–44.
67. **Thompson M**, Harnden A, Perera R, *et al*. Deriving temperature and age appropriate heart rate centiles for children with acute infections. *Arch Dis Child* 2009;**94**:361–5.
68. **Smyth A**, Carty H, Hart CA. Clinical predictors of hypoxaemia in children with pneumonia. *Ann Trop Paediatr* 1998;**18**:31–40.
69. **Palafox M**, Guiscafe H, Reyes H, *et al*. Diagnostic value of tachypnoea in pneumonia defined radiologically. *Arch Dis Child* 2000;**82**:41–5.
70. **Harnden A**, Perera R, Brueggemann AB, *et al*. Respiratory infections for which general practitioners consider prescribing an antibiotic: a prospective study. *Arch Dis Child* 2007;**92**:594–7.
71. **Harari M**, Shann F, Spooner V, *et al*. Clinical signs of pneumonia in children. *Lancet* 1991;**338**:928–30.
72. **Cherian T**, John TJ, Simoes E, *et al*. Evaluation of simple clinical signs for the diagnosis of acute lower respiratory tract infection. *Lancet* 1988;**11**:125–8.
73. **Mahabee-Gittens EM**, Grupp-Phelan J, Brody AS, *et al*. Identifying children with pneumonia in the emergency department. *Clin Pediatr* 2005;**44**:427–35.
74. **Esposito S**, Bosis S, Cavagna R, *et al*. Characteristics of Streptococcus pneumoniae and atypical bacterial infections in children 2-5 years of age with community-acquired pneumonia. *Clin Infect Dis* 2002;**35**:1345–52.
75. **March M**, Sant'Anna CC. Signs and symptoms indicative of community-acquired pneumonia in infants under six months. *Braz J Infect Dis* 2005;**9**:150–5.
76. **Klig JE**. Office pediatrics: current perspectives on the outpatient evaluation and management of lower respiratory infections in children. *Curr Opin Pediatr* 2006;**18**:71–6.
77. **Korppi M**, Don M, Valent F, *et al*. The value of clinical features in differentiating between viral, pneumococcal and atypical bacterial pneumonia in children. *Acta Paediatr* 2008;**97**:943–7.
78. **Broughton RA**. Infections due to Mycoplasma pneumoniae in childhood. *Pediatr Infect Dis J* 1986;**5**:71–85.
79. **NICE**. *Feverish Illness in Children—Assessment and Initial Management in Children Younger than 5 years*. CG47. London: National Institute for Health and Clinical Excellence, 2007.

80. **Hazir T**, Nisar YB, Qazi SA, *et al*. Chest radiography in children aged 2-59 months diagnosed with non-severe pneumonia as defined by World Health Organization: descriptive multicentre study in Pakistan. *BMJ* 2006;**333**:629.
81. **Redd SC**, Patrick E, Vreuls R, *et al*. Comparison of the clinical and radiographic diagnosis of paediatric pneumonia. *Trans R Soc Trop Med Hyg* 1994;**88**:307–10.
82. **Zar HJ**, Jeena P, Argent A, *et al*. Diagnosis and management of community-acquired pneumonia in childhood: South African Thoracic Society guidelines. *S Afr Med J* 2005;**95**:977–89.
83. **Rigsby CK**, Strife JL, Johnson ND, *et al*. Is the frontal radiograph alone sufficient to evaluate for pneumonia in children? *Pediatr Radiol* 2004;**34**:379–83.
84. **Kiekara O**, Korppi M, Tanska S, *et al*. Radiological diagnosis of pneumonia in children. *Ann Med* 1996;**28**:69–72.
85. **World Health Organization**. *WHO Model Chapter for Textbooks: IMCI, Integrated Management of Childhood Illness*. Geneva: World Health Organization, 2001.
86. **Toikka P**, Irljola K, Juven T, *et al*. Serum procalcitonin, C-reactive protein and interleukin-6 for distinguishing bacterial and viral pneumonia in children. *Pediatr Infect Dis J* 2000;**19**:598–602.
87. **Virkki R**, Juven T, Rikalainen H, *et al*. Differentiation of bacterial and viral pneumonia in children. *Thorax* 2002;**57**:438–41.
88. **Virkki R**, Juven T, Mertsola J, *et al*. Radiographic follow-up of pneumonia in children. *Pediatr Pulm* 2005;**40**:223–7.
89. **Suren P**, Try K, Eriksson J, *et al*. Radiographic follow-up of community-acquired pneumonia in children. *Acta Paediatr* 2008;**97**:46–50.
90. **Korppi M**, Remes S, Heiskanen-Kosma T. Serum procalcitonin concentrations in bacterial pneumonia in children: a negative result in primary healthcare settings. *Pediatr Pulm* 2003;**35**:56–61.
91. **Don M**, Valent F, Korppi M, *et al*. Efficacy of serum procalcitonin in evaluating severity of community-acquired pneumonia in childhood. *Scand J Infect Dis* 2007;**39**:129–37.
92. **Don M**, Valent F, Korppi M, *et al*. Differentiation of bacterial and viral community-acquired pneumonia in children. *Pediatr Int* 2009;**51**:91–6.
93. **Michelow IC**, Katz K, McCracken GH, *et al*. Systemic cytokine profile in children with community-acquired pneumonia. *Pediatr Pulm* 2007;**42**:640–5.
94. **Flood RG**, Badik J, Aronoff SC. The utility of serum C-reactive protein in differentiating bacterial from nonbacterial pneumonia in children: a meta-analysis of 1230 children. *Pediatr Infect Dis J* 2008;**27**:95–9.
95. **Heiskanen-Kosma T**, Korppi M. Serum C-reactive protein cannot differentiate bacterial and viral aetiology of community-acquired pneumonia in children in primary healthcare settings. *Scand J Infect Dis* 2000;**32**:399–402.
96. **Moulin F**, Raymond J, Lorrot M, *et al*. Procalcitonin in children admitted to hospital with community acquired pneumonia. *Arch Dis Child* 2001;**84**:332–6.
97. **Lambert SB**, Whitley DM, O'Neill NT, *et al*. Comparing nose-throat swabs and nasopharyngeal aspirates collected from children with symptoms for respiratory virus identification using real-time polymerase chain reaction. *Pediatrics* 2008;**122**:e615–20.
98. **Korppi M**. Pneumococcal serology in children's respiratory infections. *Eur J Clin Microbiol* 2008;**27**:167–75.
99. **Fletcher M**, Leeming J, Cartwright K, *et al*. Childhood empyema: limited potential impact of 7-valent pneumococcal conjugate vaccine. *Pediatr Infect Dis J* 2006;**25**:559–60.
100. **Le Monnier A**, Carbonelle E, Zahar J-R, *et al*. Microbiological diagnosis of empyema in children: comparative evaluations by culture, polymerase chain reaction, and pneumococcal antigen detection in pleural fluids. *Clin Infect Dis* 2006;**42**:1135–40.
101. **Charkaluk M-L**, Kalach N, Mvogo H, *et al*. Assessment of a rapid urinary antigen detection by an immunochromatographic test for diagnosis of pneumococcal infection in children. *Diagn Microbiol Infect Dis* 2006;**55**:89–94.
102. **Rajalakshmi B**, Kanungo R, Srinivasan S, *et al*. Pneumolysin in urine: a rapid antigen detection method to diagnose pneumococcal pneumonia in children. *Indian J Med Microbiol* 2002;**20**:183–6.
103. **Michelow IC**, Olsen K, Lozano J, *et al*. Diagnostic utility and clinical significance of naso- and oropharyngeal samples used in a PCR assay to diagnose Mycoplasma pneumoniae infection in children with community-acquired pneumonia. *J Clin Microbiol* 2004;**42**:3339–41.
104. **Dagan R**, Shriker O, Hazan I, *et al*. Prospective study to determine clinical relevance of detection of pneumococcal DNA in sera of children by PCR. *J Clin Microbiol* 1998;**36**:669–73.
105. **Maltezou HC**, La-Scola B, Astra H, *et al*. Mycoplasma pneumoniae and Legionella pneumophila in community-acquired lower respiratory tract infections among hospitalized children: diagnosis by real time PCR. *Scand J Infect Dis* 2004;**36**:639–42.
106. **Nilsson AC**, Bjorkman P, Persson K. Polymerase chain reaction is superior to serology for the diagnosis of acute Mycoplasma pneumoniae infection and reveals a high rate of persistent infection. *BMC Microbiol* 2008;**8**:93.
107. **Shetty AK**, Treyner E, Hill DW, *et al*. Comparison of conventional viral cultures with direct fluorescent antibody stains for diagnosis of community-acquired respiratory virus infections in hospitalized children. *Pediatr Infect Dis J* 2003;**22**:789–94.
108. **Thompson M**, Coad N, Harnden A, *et al*. How well do vital signs identify children with serious infections in paediatric emergency care? *Arch Dis Child* 2009;**94**:888–93.
109. **Langley JM**, Bradley JS. Defining pneumonia in critically ill infants and children. *Pediatr Crit Care Med* 2005;**6**:S9–13.
110. **Margenthaler JA**, Weber TR, Keller MS. Predictors of surgical outcome for complicated pneumonia in children: impact of bacterial virulence. *World J Surg* 2004;**28**:87–91.
111. **Bharti B**, Bharti S, Verma V. Role of Acute Illness Observation Scale (AIOS) in managing severe childhood pneumonia. *Indian J Pediatr* 2007;**74**:27–32.
112. **Lin C-J**, Chen P-Y, Huang F-L, *et al*. Radiographic, clinical, and prognostic features of complicated and uncomplicated community-acquired lobar pneumonia in children. *J Microbiol Immunol* 2006;**39**:489–95.
113. **Balfour-Lynn IM**, Abrahamson E, Cohen G, *et al*. BTS guidelines for the management of pleural infection in children. *Thorax* 2005;**60**(Suppl 1):i1–21.
114. **Chang CC**, Cheng AC, Chang AB. Over-the-counter (OTC) medications to reduce cough as an adjunct to antibiotics for acute pneumonia in children and adults. *Cochrane Database Syst Rev* 2007;(4):CD006088.
115. **Kumar RM**, Kabra SK, Singh M. Efficacy and acceptability of different modes of oxygen administration in children: implications for a community hospital. *J Trop Pediatr* 1997;**43**:47–9.
116. **van Someren V**, Linnett SJ, Stothers JK, *et al*. An investigation into the benefits of resiting nasoenteric feeding tubes. *Pediatrics* 1984;**73**:379–83.
117. **Sporik R**. Why block a small hole? The adverse affects of nasogastric tubes. *Arch Dis Child* 1994;**71**:393–4.
118. **Anon**. *Reducing the Risk of Hyponatraemia when Administering Intravenous Fluids to Children*. NHS National Patient Safety Agency, 2007 Contract No: Patient Safety Alert Number 22.
119. **Britton S**, Bejsted M, Vedin L. Chest physiotherapy in primary pneumonia. *BMJ (Clin Res Ed)* 1985;**290**:1703–4.
120. **Levine A**. Chest physical therapy for children with pneumonia. *J Am Osteopath Assoc* 1978;**78**:122–5.
121. **Gilchrist FJ**. Is the use of chest physiotherapy beneficial in children with community acquired pneumonia? *Arch Dis Child* 2008;**93**:176–8.
122. **Stapleton T**. Chest physiotherapy in primary pneumonia. *BMJ* 1985;**291**:143.
123. **Tsarouhas N**, Shaw KN, Hodinka RL, *et al*. Effectiveness of intramuscular penicillin versus oral amoxicillin in the early treatment of outpatient pediatric pneumonia. *Pediatr Emerg Care* 1998;**14**:338–41.
124. **Friis B**, Andersen P, Brenoe E, *et al*. Antibiotic treatment of pneumonia and bronchiolitis. A prospective randomised study. *Arch Dis Child* 1984;**59**:1038–45.
125. **Agarwal G**, Awasthi S, Kabra SK, *et al*. Three day versus five day treatment with amoxicillin for non-severe pneumonia in young children: a multicentre randomised controlled trial [erratum appears in *BMJ* 2004;**328**:1066]. *BMJ* 2004;**328**:791.
126. **Awasthi S**, Agarwal G, Kabra SK, *et al*. Does 3-day course of oral amoxicillin benefit children of non-severe pneumonia with wheeze: a multicentric randomised controlled trial. *PLoS ONE* 2008;**3**:e1991.
127. **Jacobs MR**, Good CE, Beall B, *et al*. Changes in serotypes and antimicrobial susceptibility of invasive Streptococcus pneumoniae strains in Cleveland: a quarter century of experience. *J Clin Microbiol* 2008;**46**:982–90.
128. **Dagan R**, Klugman KP. Impact of conjugate pneumococcal vaccines on antibiotic resistance. *Lancet Infect Dis* 2008;**8**:785–95.
129. **Richter SS**, Heilmann KP, Dohrn CL, *et al*. Changing epidemiology of antimicrobial-resistant Streptococcus pneumoniae in the United States, 2004–2005. *Clin Infect Dis* 2009;**48**:e23–33.
130. **Jacobs MR**. Antimicrobial-resistant Streptococcus pneumoniae: trends and management. *Expert Rev Anti Infect Ther* 2008;**6**:619–35.
131. **Jacobs MR**, Dagan R. Antimicrobial resistance among pediatric respiratory tract infections: clinical challenges. *Semin Pediatr Infect Dis* 2004;**15**:5–20.
132. **Farrell DJ**, File TM, Jenkins SG. Prevalence and antibacterial susceptibility of mef (A)-positive macrolide-resistant Streptococcus pneumoniae over 4 years (2000 to 2004) of the PROTEKT US Study. *J Clin Microbiol* 2007;**45**:290–3.
133. **Dias R**, Canica M. Trends in resistance to penicillin and erythromycin of invasive pneumococci in Portugal. *Epidemiol Infect* 2008;**136**:928–39.
134. **Muller-Pebody B**, Johnson A, Lillie M, *et al*. *Antimicrobial Resistance and Prescribing in England, Wales and Northern Ireland, 2008*. London: Health Protection Agency, 2008.
135. **Beasley L**, Pichon B, Martin S, *et al*. *Genetic Determinants of Antibiotic Resistance in Pneumococci Causing Invasive Pneumococcal Disease in Children in Relation to the Introduction of Prevenar in the UK [Poster]*. HPA Warwick conference; Warwick: HPA, 2008.
136. **Beekmann SE**, Heilmann KP, Richter SS, *et al*. Antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis and group A beta-haemolytic streptococci in 2002-2003. Results of the multinational GRASP Surveillance Program. *Int J Antimicrob Agents* 2005;**25**:148–56.
137. **Alfaro C**, Fergie J, Purcell K. Emergence of community-acquired methicillin-resistant Staphylococcus aureus in complicated parapneumonic effusions. *Pediatr Infect Dis J* 2005;**24**:274–6.
138. **Clements H**, Stephenson T, Gabriel V, *et al*. Rationalised prescribing for community acquired pneumonia: a closed loop audit. *Arch Dis Child* 2000;**83**:320–4.
139. **Tan TO**, Mason EO Jr, Barson WJ, *et al*. Clinical characteristics and outcome of children with pneumonia attributable to penicillin-susceptible and penicillin-nonsusceptible Streptococcus pneumoniae. *Pediatrics* 1998;**102**:1369–75.
140. **Friedland IR**. Comparison of the response to antimicrobial therapy of penicillin-resistant and penicillin-susceptible pneumococcal disease. *Pediatr Infect Dis J* 1995;**14**:885–90.
141. **Paganini H**, Guinazu JR, Hernandez C, *et al*. Comparative analysis of outcome and clinical features in children with pleural empyema caused by penicillin-nonsusceptible and penicillin-susceptible Streptococcus pneumoniae. *Int J Infect Dis* 2001;**5**:86–8.

142. **Buckingham SC**, McCullers JA, Lujan-Zilbermann J, *et al*. Pneumococcal meningitis in children: relationship of antibiotic resistance to clinical characteristics and outcomes. *Pediatr Infect Dis J* 2001;**20**:837–43.
143. **Malhotra-Kumar S**, Lammens C, Coenen S, *et al*. Effect of azithromycin and clarithromycin therapy on pharyngeal carriage of macrolide-resistant streptococci in healthy volunteers: a randomised, double-blind, placebo-controlled study. *Lancet* 2007;**369**:482–90.
144. **Lonks JR**. What is the clinical impact of macrolide resistance? *Curr Infect Dis Rep* 2004;**6**:7–12.
145. **Yanagihara K**, Izumikawa K, Higa F, *et al*. Efficacy of azithromycin in the treatment of community-acquired pneumonia, including patients with macrolide-resistant Streptococcus pneumoniae infection. *Intern Med* 2009;**48**:527–35.
146. **Feikin DR**, Schuchat A, Kolczak M, *et al*. Mortality from invasive pneumococcal pneumonia in the era of antibiotic resistance, 1995–1997. *Am J Public Health* 2000;**90**:223–9.
147. **Klein M**. Multicenter trial of cefpodoxime proxetil vs. amoxicillin-clavulanate in acute lower respiratory tract infections in childhood. International Study Group. *Pediatr Infect Dis J* 1995;**14**(Suppl 4):S19–22.
148. **Amir J**, Harel L, Eidlitz-Markus T, *et al*. Comparative evaluation of cefixime versus amoxicillin-clavulanate following ceftriaxone therapy of pneumonia. *Clin Pediatr (Phila)* 1996;**35**:629–33.
149. **Galova K**, Sufliarska S, Kukova Z, *et al*. Multicenter randomized study of two once daily regimens in the initial management of community-acquired respiratory tract infections in 163 children: azithromycin versus cefbuten. *Chemotherapy* 1996;**42**:231–4.
150. **Vuori-Holopainen E**, Peltola H, Kallio MJT. Narrow- versus broad-spectrum parenteral antimicrobials against common infections of childhood: a prospective and randomised comparison between penicillin and cefuroxime. *Eur J Pediatr* 2000;**159**:878–84.
151. **Ferwerda A**, Moll HA, Hop WC, *et al*. Efficacy, safety and tolerability of 3 day azithromycin versus 10 day co-amoxiclav in the treatment of children with acute lower respiratory tract infections. *J Antimicrob Chemother* 2001;**47**:441–6.
152. **Aurangzeb B**, Hameed A. Comparative efficacy of amoxicillin, cefuroxime and clarithromycin in the treatment of community-acquired pneumonia in children. *J Coll Physicians Surg Pak* 2003;**13**:704–7.
153. **Bradley JS**, Arguedas A, Blumer JL, *et al*. Comparative study of levofloxacin in the treatment of children with community-acquired pneumonia. *Pediatr Infect Dis J* 2007;**26**:868–78.
154. **Manfredi R**, Jannuzzi C, Mantero E, *et al*. Clinical comparative study of azithromycin versus erythromycin in the treatment of acute respiratory tract infections in children. *J Chemother* 1992;**4**:364–70.
155. **Ficnar B**, Huzjak N, Oreskovic K, *et al*. Azithromycin: 3-day versus 5-day course in the treatment of respiratory tract infections in children. Croatian Azithromycin Study Group. *J Chemother* 1997;**9**:38–43.
156. **Lee P-I**, Wu M-H, Huang L-M, *et al*. An open, randomized, comparative study of clarithromycin and erythromycin in the treatment of children with community-acquired pneumonia. *J Microbiol Immunol* 2008;**41**:54–61.
157. **Kabra SK**, Lodha R, Pandey RM. Antibiotics for community acquired pneumonia in children. *Cochrane Database Syst Rev* 2006;(3):CD004874.
158. **Hazir T**, Fox LM, Nisar YB, *et al*. Ambulatory short-course high-dose oral amoxicillin for treatment of severe pneumonia in children: a randomised equivalency trial. *Lancet* 2008;**371**:49–56.
159. **Fonseca W**, Hoppu K, Rey LC, *et al*. Comparing pharmacokinetics of amoxicillin given twice or three times per day to children older than 3 months with pneumonia. *Antimicrob Agents Chemother* 2003;**47**:997–1001.
160. **Hazir T**, Qazi SA, Bin Nisar Y, *et al*. Comparison of standard versus double dose of amoxicillin in the treatment of non-severe pneumonia in children aged 2–59 months: a multi-centre, double blind, randomised controlled trial in Pakistan. *Arch Dis Child* 2007;**92**:291–7.
161. **Shames JM**, George RB, Holliday WB, *et al*. Comparison of antibiotics in the treatment of mycoplasmal pneumonia. *Arch Intern Med* 1970;**125**:680–4.
162. **Tagliabue C**, Salvatore CM, Techasaensiri C, *et al*. The impact of steroids given with macrolide therapy on experimental Mycoplasma pneumoniae respiratory infection. *J Infect Dis* 2008;**198**:1180–8.
163. **Lu Y-J**, Chen T-H, Lin L-H, *et al*. Macrolide use shortens fever duration in Mycoplasma pneumoniae infection in children: a 2-year experience. *J Microbiol Immunol* 2008;**41**:307–10.
164. **Mulholland S**, Gavranich JB, Chang AB. Antibiotics for community-acquired lower respiratory tract infections secondary to Mycoplasma pneumoniae in children. *Cochrane Database Syst Rev* 2010;(7):CD004875.
165. **Addo-Yobo E**, Chisaka N, Hassan M, *et al*. Oral amoxicillin versus injectable penicillin for severe pneumonia in children aged 3 to 59 months: a randomised multicentre equivalency study. *Lancet* 2004;**364**:1141–8.
166. **Atkinson M**, Lakanpaul M, Smyth A, *et al*. Comparison of oral amoxicillin and intravenous benzyl penicillin for community acquired pneumonia in children (PIVOT trial): a multicentre pragmatic randomised controlled equivalence trial. *Thorax* 2007;**62**:1102–6.
167. **Rojas MX**, Granados Rugeles C. Oral antibiotics versus parenteral antibiotics for severe pneumonia in children. *Cochrane Database Syst Rev* 2006;(2):CD004979.
168. **Haider B**, Saeed M, Bhutta Z. Short-course versus long-course antibiotic therapy for non-severe community-acquired pneumonia in children aged 2 months to 59 months. *Cochrane Database Syst Rev* 2008;(2):CD005976.
169. **Qazi S**. Clinical efficacy of 3 days versus 5 days of oral amoxicillin for treatment of childhood pneumonia: a multicentre double-blind trial. *Lancet* 2002;**360**:835–41.
170. **Deeks SL**, Palacio R, Ruvinsky R, *et al*. Risk factors and course of illness among children with invasive penicillin-resistant Streptococcus pneumoniae. The Streptococcus pneumoniae Working Group. *Pediatrics* 1999;**103**:409–13.
171. **Chonmaitree T**, Powell KR. Parapneumonic pleural effusion and empyema in children. Review of a 19-year experience, 1962–1980. *Clin Pediatr* 1983;**22**:414–19.
172. **Hamm H**, Light RW. Parapneumonic effusion and empyema. *Eur Respir J* 1997;**10**:1150–6.
173. **Buckingham SC**, King MD, Miller ML. Incidence and etiologies of complicated parapneumonic effusions in children, 1996 to 2001. *Pediatr Infect Dis J* 2003;**22**:499–504.
174. **Byington CL**, Spencer LY, Johnson TA, *et al*. An epidemiological investigation of a sustained high rate of pediatric parapneumonic empyema: risk factors and microbiological associations. *Clin Infect Dis* 2002;**34**:434–40.
175. **Ramphul N**, Eastham KM, Freeman R, *et al*. Cavitory lung disease complicating empyema in children. *Pediatr Pulmonol* 2006;**41**:750–3.
176. **Sowicki GS**, Lu FL, Valim C, *et al*. Necrotising pneumonia is an increasingly detected complication of pneumonia in children. *Eur Respir J* 2008;**31**:1285–91.
177. **Cowles RA**, Lelli JL, Takayasu J, *et al*. Lung resection in infants and children with pulmonary infections refractory to medical therapy. *J Pediatr Surg* 2002;**37**:643–7.
178. **Gillet Y**, Vanhems P, Lina G, *et al*. Factors predicting mortality in necrotizing community acquired pneumonia caused by Staphylococcus aureus containing Panton-Valentine leukocidin. *Clin Infect Dis* 2007;**45**:315–21.
179. **Donnelly LF**, Klosterman LA. The yield of CT of children who have complicated pneumonia and noncontributory chest radiography. *Am J Roentgenol* 1998;**170**:1627–31.
180. **Patradoon-Ho P**, Fitzgerald DA. Lung abscess in children. *Paediatr Respir Rev* 2007;**8**:77–84.
181. **Waters AM**, Kerecuk L, Luk D, *et al*. Hemolytic uremic syndrome associated with invasive pneumococcal disease: the United Kingdom experience. *J Pediatr* 2007;**151**:140–4.
182. **Ceruti E**, Contreras J, Neira M. Staphylococcal pneumonia in childhood. Long-term follow-up including pulmonary function studies. *Am J Dis Child* 1971;**122**:386–92.
183. **Soto M**, Demis T, Landau LI. Pulmonary function following staphylococcal pneumonia in children. *Aust Paediatr J* 1983;**19**:172–4.
184. **Creech CB**, Johnson BG, Bartilson RE, *et al*. Increasing use of extracorporeal life support in methicillin-resistant Staphylococcus aureus sepsis in children. *Paediatr Crit Care Med* 2007;**8**:231–5.
185. **Hill SC**, Liang L. Smoking in the home and children's health. *Tob Control* 2008;**17**:32–7.
186. **Madhi SA**, Levine OS, Hajjeh R, *et al*. Vaccines to prevent pneumonia and improve child survival. *Bull World Health Organ* 2008;**86**:365–72.
187. **Mulholland K**, Hilton S, Adegbola R, *et al*. Randomised trial of Haemophilus influenzae type-b tetanus protein conjugate vaccine [corrected] for prevention of pneumonia and meningitis in Gambian infants. *Lancet* 1997;**349**:1191–7.
188. **de Andrade ALSS**, de Andrade JG, Martelli CMT, *et al*. Effectiveness of Haemophilus influenzae b conjugate vaccine on childhood pneumonia: a case-control study in Brazil. *Int J Epidemiol* 2004;**33**:173–81.
189. **Watt JP**, Wolfson LJ, O'Brien KL, *et al*. Burden of disease caused by Haemophilus influenzae type b in children younger than 5 years: global estimates. *Lancet* 2009;**374**:903–11.
190. **Greenberg DP**, von Konig CH, Heininger U. Health burden of pertussis in infants and children. *Pediatr Infect Dis J* 2005;**24**(Suppl 5):S39–43.
191. **CDC**. Pertussis—United States. *MMWR Morb Mortal Wkly Rep*. 2002;**51**:73–6.
192. **Hansen J**, Black S, Shinefield H, *et al*. Effectiveness of heptavalent pneumococcal conjugate vaccine in children younger than 5 years of age for prevention of pneumonia: updated analysis using World Health Organization standardized interpretation of chest radiographs. *Pediatr Infect Dis J* 2006;**25**:779–81.
193. **Grijalva CG**, Nuorti JP, Arbogast PG, *et al*. Decline in pneumonia admissions after routine childhood immunisation with pneumococcal conjugate vaccine in the USA: a time-series analysis. *Lancet* 2007;**369**:1179–86.
194. **Poehling KA**, Lafleur BJ, Szilagyi PG, *et al*. Population-based impact of pneumococcal conjugate vaccine in young children. *Pediatrics* 2004;**114**:755–61.
195. **Zhou F**, Kyaw MH, Shefer A, *et al*. Health care utilization for pneumonia in young children after routine pneumococcal conjugate vaccine use in the United States. *Arch Pediatr Adolesc Med* 2007;**161**:1162–8.
196. **Nelson JC**, Jackson M, Yu O, *et al*. Impact of the introduction of pneumococcal conjugate vaccine on rates of community acquired pneumonia in children and adults. *Vaccine* 2008;**26**:4947–54.
197. **Esposito S**, Lizioli A, Lastrico A, *et al*. Impact on respiratory tract infections of heptavalent pneumococcal conjugate vaccine administered at 3, 5 and 11 months of age. *Respir Res* 2007;**8**:12.
198. *Invasive Pneumococcal Disease (IPD) in England and Wales after 7-valent Conjugate Vaccine (PCV7); Potential Impact of 10 and 13-valent Vaccines [database on the Internet]*. Health Protection Agency, 2009. http://www.hpa.org.uk/web/HPAwebFile/HPAweb_C/1245581527892 (accessed Jan 2010).
199. **Reichert TA**, Sugaya N, Fedson DS, *et al*. The Japanese experience with vaccinating schoolchildren against influenza. *N Engl J Med* 2001;**344**:889–96.
200. **Kwong JC**, Stukel TA, Lim J, *et al*. The effect of universal influenza immunization on mortality and health care use. *PLoS Med* 2008;**5**:e211.